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ABSTRACT 
 
Chemoattractants and chemoattractant receptors have many important functions in 
multicellular organisms, not least for their role in regulating migration of leukocytes. 
The receptors are also involved in many pathologies and they have, since they were 
cloned in the 1990ies, been regarded as attractive targets for development of drugs 
against cancer, viral infections, and inflammatory/autoimmune diseases.  
 
Although chemotactic molecules are very heterogeneous in terms of chemical structure 
most of them mediate their actions through binding to a G-protein-coupled receptor 
(GPCR). The formyl peptide receptors (FPRs) are chemoattractant receptors expressed 
on phagocytes and have important implications in host defense and inflammation as 
well as in resolution of inflammation. One of the goals was to identify FPR2 specific 
ligands with similar anti-inflammatory and proresolution properties as the eicosanoid 
lipoxin A4 previously described. A small compound library was screened for both 
agonist and antagonists and selected compounds were analyzed with respect to anti-
inflammatory properties such as inhibition of NADPH oxidase activity and 
degranulation in primary neutrophils. Receptor selectivity was investigated by 
compound stimulation and desensitization studies in presence of receptor-specific tools. 
While the agonist screen resulted in non selective hit compounds with proinflammatory 
properties, the antagonist screen led to identification of anti-inflammatory agents with 
different selectivity.   
 
Another chemoattractant receptor binds CCL2, a member of the superfamily of 
chemokines. The function of CCL2 and its receptor (CCR2) is of importance for 
monocyte recruitment, and together this receptor ligand pair has many implications in 
inflammation. Accordingly, the importance of the CCL2/CCR2 axis in the recruitment 
of inflammatory cells and fibroblasts into fibrotic tissues was hypothesized as a 
mechanism for induction of fibrosis. There is, however, emerging evidence indicating 
that CCL2 may promote fibrosis also by other mechanisms such as activation of the 
fibroblast. The myofibroblast, synthesizing large amounts of extracellular matrix 
components (ECM) in response to profibrotic cytokines and growth factors, is the key 
cell in fibrosis. The effects of CCL2 on human fibroblasts with respect to ECM 
expression were studied and it was found that CCL2 might have a more multifaceted 
role in fibroblast activation than previously described. 
  
The truncated form of CCL2, CCL2 (1,9-76), also known as 7ND, is a receptor 
antagonist and is described to have therapeutic effects in several animal disease models 
such as bleomycin-induced lung fibrosis. The interaction between the 7ND and the 
human as well as the murine CCR2 was studied in vitro and data showed that 7ND was 
an inhibitor of human CCR2 but a very low affinity binder of the murine receptor. 7ND 
was, however, shown to downregulate fibrotic markers in murine fibroblasts, but in 
accordance with its inability to bind CCR2 the downregulation was found to be 
independent of this receptor. 
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1  INTRODUCTION 
 
The immune system is vital to defend us from microorganisms and contribute to tissue 
injury repair. In response to foreign invaders as well as trauma, inflammatory responses 
are orchestered by a large number of different inflammatory cells recruited to the site of 
inflammation where they kill microorganisms and contribute to wound repair. 
 
Recruitment of inflammatory cells is mediated by chemottractants. They are important 
signaling molecules of different sizes and structures that integrate important functions 
in inflammation. Chemoattractants bind to chemoattractant receptors on immune cells 
and induce migration and other crucial functions of the inflammatory cells.  
 
Dysregulations of the inflammatory response and tissue repair may lead to chronic 
inflammation and autoinflammatory disease as well as fibroproliferative disorders. 
Traditionally, inflammatory diseases are treated with NSAIDs and glucocorticosteroids, 
and the latest contribution is the large group of antibodies and antibody-like drugs such 
as the TNFα-inhibitors. However, several inflammatory disorders, together with 
fibrotic diseases still constitute a large medical need of new drugs.   
 
With their important roles in inflammatory responses, chemoattractant and their 
receptors are interesting targets for development of new drugs. By modulation of their 
responses, the goal is to slow down harmful immune reactions and prevent chronic 
inflammation. The first drug candidates are in progress and hopefully we will see new 
such anti-inflammmatory drugs on the market within the next few years.  
 
In this thesis different strategies to modulate the responses of chemoattractant 
receptors, together with associated opportunities and challenges, are discussed. 
Experiences will be discussed based on research of two chemoattractant receptors; 
identification and characterization of small molecule modulators of the FPR receptors 
and characterization of a previously described peptide antagonist of the CCR2 receptor 
for anti-inflammatory/antifibrotic therapeutic use. 
 
 
1.1  Immune reactions and host defense 	  
We are constantly exposed to different types of potentially harmful microorganisms 
and as a part of our daily life we need to defend ourselves from such attacks. We also 
sometimes run into slight or serious injury and these threats to our health are handled in 
our body by reactions aiming to heal and repair. 
 
The innate immune system is the first line of our defense against microorganisms and 
many parts of the system were developed long before adaptive immunity. Innate 
immunity is universal, acting within minutes upon stimulation. In brief the innate 
immune system relies on three foundations, i) recognition of pathogens, ii) ability to 
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kill these pathogens and, iii) sparing the host tissues or being self-tolerant. The innate 
immune apparatus is built up by cellular as well as humoral components and these two 
parts can be attributed to recognition and/or effector functions that interact in a complex 
network [1].  
 
The major cellular components are patrolling professional phagocytes of myeloid 
origin that seek invading microbes and when these are recognized they should be 
engulfed and killed. Among these patrolling cells are macrophages which are 
distributed throughout the body and they are always ready for action. Macrophages also 
have supervising and organizing roles in both innate and adaptive immunity. By 
elaboration of chemoattractants they also recruit other myeloid cells expressing 
chemoattractant receptors to the site of infection. The neutrophil granulocyte is one 
such cell, a specialized killer endowed with a broad array of weapons and of prime 
importance in innate immunity [1]. 
 
Phagocytes are equipped with receptor structures that react to all kinds of threats, so-
called danger signals that are recognized by surface and endosomal receptors. Toll-like 
receptors (TLRs) [2, 3] and formyl peptide receptors (FPRs) [4] are examples of such 
recognition structures. Microbial derived pathogen-associated molecular patterns 
(PAMP), and damage- associated molecular patterns (DAMP) [5] as well as cytosolic 
or nuclear proteins are examples of signaling molecules. When these are host derived, 
they are normally not exposed but released through trauma.  
 
Recognition of a danger signal initiates a cell based effector cascade involving among 
other potential tissue destructing molecules such as reactive oxygen species. These are 
produced by an enzyme complex termed the phagocyte NADPH oxidase [6]. Autocoid 
substances such as histamine and bradykinin that cause local vasodilatation and 
cytokines such as interleukin-1 and TNFα that stimulate the endothelial lining of the 
vessels to upregulate adhesion molecules, are also parts of the cascade.  Mobilization of 
adhesion molecules results in the slowing down of circulating leukocytes and 
progressively increased adhesion of cells to the endothelial cell layer facilitating the 
next recruitment step, migration from blood into the inflamed tissue [7].  
 
Some antigens are not neutralized by the innate immune system but will be taken up by 
highly specified antigen-presenting cells (APC), dendritic cells or macrophages and 
transported via the lymph to the lymph nodes. In the lymph nodes the antigen will be 
presented in complex with major histocompatibility complex molecules (MHC) on the 
surface of APC to naïve T-cells. Activated APC upregulate co-stimulatory molecules 
that synergize with naïve T-cells and contribute to the activation of the naïve T-cell. 
The T-cell has become an armed effector T-cell acting in specific against cells carrying 
the antigen. 
 
The activated T-cell initiates the synthesis of interleukin-2 which promotes the 
proliferation and differentiation of the activated T cell. The activation may give rise to 
different subtypes of T-cells, cytotoxic CD8, CD4 Th1 and CD4 Th2 T-cells depending 
on which antigen is presented to the naïve T cell [8]. Cytotoxic CD8 T cells have the 
capability to directly kill target cells carrying the antigen while CD4 cells act through 
activation of macrophages by interferonγ or by activation of B-cells. B-cells can also be 
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activated directly by microbial antigens. The activated B-cells proliferate and 
differentiate to plasma cells secreting antibodies specific to the triggering antigen.  
 
Activation of T and B- cells is part of the adaptive immune system. This system when 
compared to the innate immune system is a more recently evolved immune response 
that is found only in vertebrates and is considered to be overlapping with the innate 
immune system. In reality the two systems are highly integrated and support each other.  
 
The humoral parts of the innate immune system include many different molecules in 
extracellular compartments. Sensing components are for example acute-phase proteins 
such as the mannose-binding protein, the lipopolysaccharide binding protein (LBP) and 
the C-reactive protein. These are synthesized in the liver upon cytokine stimulation and 
bind either directly to microbes or to constituents with a bacterial origin. Elaboration of 
acute-phase proteins has systemic effects and is one component of the inflammation 
reaction that causes fever. Other effector molecules of importance for the humoral 
innate immune system include complement components, lysozyme, lactoferrin and 
antimicrobial proteins/peptides acting by destroying bacterial cell walls or biological 
membranes [9].  
 
In addition to cytokines, prostanoids and leukotrienes are important proinflammatory 
mediators. Phospholipase A2 cleaves phospholipids in the cell membrane and 
arachidonic acid (AA) is formed and released. This constitutes the backbone of 
prostanoids synthesized by the enzymes cyclooxygenase-1 and 2 (COX-1, COX-2) or 
leukotrienes formed by lipooxygenase (5-LOX). The subclass of prostanoids includes 
the prostaglandins, thromboxanes and prostacyclins. These lipid mediators, acting via 
both autocrine and paracrine mechanisms have several proinflammatory effects. These 
include inducing vasodilatation of blood vessels, cell migration and cell damage 
causing typical reactions of inflammation, fever, redness and pain [10]. 
 
Resolution of inflammation is the process leading to homeostasis and restored tissue 
and this will be further discussed in chapter 3.2. 
 
 
1.2  Inflammation and fibrosis-two pathologies related to 
dysregulations of the immune response 	  
Inflammation 
 
The hallmark of invading microbes or injury is an inflammatory reaction aiming to heal 
and repair. Acute events are immediate and lead to local swelling, redness, pain, heat 
and sometimes dysfunction of the affected organs. These manifestations are caused by 
increased blood flow, relaxing effects on blood vessels, release of proinflammatory 
mediators, extravasation of fluids from blood and lymph vessels into the infested tissue 
and influx of proinflammatory cells. Normally the inflamed tissue/organ is healed after 
a couple of days but in exceptional cases the inflammation is extended. The 
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inflammation may be provoked by persistence of an infectious organism, a nonliving 
irritant material or an abnormality in the host’s response to its own tissue. 
 
The exact mechanisms and causes of autoimmunity/autoinflammation is an emerging 
field and much research still remains to be carried out before we understand the 
complexity and how the immune system sometimes fails, with disease instead of 
protection as the final outcome. When the immune system recognizes a “self 
molecule”, the response results in the development of autoreactive effector cells or 
formation of autoreactive antibodies, a scenario that might develop into a chronic 
autoimmune disease [11]. Emerging evidence shows that cells traditionally associated 
with the innate as well as the adaptive immune systems may be involved in the 
development of autoimmunity. The chronic inflamed tissue is characterized by 
infiltration of aggressive inflammatory effector cells together with increased levels of 
proinflammatory mediators that inevitably cause tissue damage. 
Autoimmune diseases can be systemic such as in Sjögrens syndrome and rheumatoid 
arthritis (RA) or affect local tissues as for example in diabetes and Crohn´s disease. 
Inflammatory diseases include many common and severe disorders, such as RA, 
multiple sclerosis (MS), psoriasis and inflammatory bowel disease (IBD).  
 
RA is a chronic inflammatory disease affecting the synovial tissue in joints of hands 
and feet. The inflammation is characterized by infiltration of inflammatory cells into 
the joints leading to swelling, proliferation of synoviocytes and pain. Infiltrating cells 
such as macrophages secrete proinflammatory factors such as TNFα, which is 
indirectly involved in the destruction of cartilage and bone resulting in disability [12, 
13]. 
 
MS is a chronic disease of the central nervous system. In similarity with many other 
inflammatory diseases, it is characterized by infiltration of inflammatory immune cells. 
Infiltration of T-cells and macrophages in the brain causes destruction of myelin sheets 
of neurons and apoptosis of myelin forming cells (oligodendrocytes). Neurons are 
affected resulting in impairment of conduction of signals leading to physical and 
cognitive disabilities [12, 14]. 
 
Psoriasis is an inflammatory skin disease characterized by red, scaly and raised plaques. 
Psoriasis is caused by a chronic cutaneous pathologic process that is driven by the 
interactions between inflammatory cells (T cells, dendritic cells, macrophages and 
neutrophils) and keratinocytes (cells of the epidermis). The disease is induced by 
infections, stress, antigenic stimuli or a secondary effect to various medications. The 
skin converts to a psoriatic lesion associated with thickening of the skin and increased 
amounts of inflammatory cells are found in the dermis [12, 14, 15].  
 
IBD is the generic name of chronic inflammatory conditions of the gastro intestinal 
tract. The most common diseases are Crohns´s disease and ulcerative colitis. The 
clinical pathology is similar but these diseases can be distinguished by different 
locations, immunological and histological patterns. However both diseases are 
postulated to be T-cell dependent, and TNFα, released from inflammatory cells is 
responsible for proinflammatory signaling [12, 16, 17]. 
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Fibrosis 
 
Fibrotic disorders are thought to have many different possible etiologies. Fibrosis is the 
end result of chronic inflammation reactions induced by different stimuli such as 
pathogenic organisms, autoimmune reactions mediated through B-cell produced auto-
antibodies, allergens or tissue components released through injury. However, in many 
cases the original cause of fibrotic disease remains unknown. Interestingly, there is 
accumulating evidence that the mechanisms driving fibrogenesis are distinct from those 
regulating inflammation [18-20]. 
 
Tissue repair (Figure 1) is a fundamental process that allows replacement of dead or 
damaged cells with new cells of the same type. But sometimes the process is 
dysregulated and normal tissue is replaced by connective tissue. The healing process 
becomes pathogenic and may result in formation of a permanent scarring of the 
affected tissue that secondarily leads to organ failure and death. Sustained production 
of growth factors such as platelet derived growth factor (PDGF), connective tissue 
growth factor (CTGF) and transforming growth factor (TGFβ), fibroblast growth factor 
(FGF), angiogenic factors (VEGF) and fibrogenic cytokines (IL-13, IL-4) and 
components of the renin-angiotensin-aldosterone system, mainly angiotensin II, 
stimulate vascular remodeling and excess deposition of extracellular cellular matrix 
components (ECM) such as collagen and fibronectin (Figure 1)[19, 21]. 
 
The key mediator of fibrosis is the activated fibroblast (the myofibroblast) over-
producing extracellular matrix proteins that accumulate in the fibrotic tissue. The 
myofibroblast phenotype may be distinguished from resident fibroblasts through its 
over expression of α-smooth muscle actin (α-SMA) and collagen type I. The 
myofibroblast may differentiate from cells of different origin; resident tissue 
fibroblasts, by epithelial mesenchymal transition (EMT) [22, 23] and circulating bone-
marrow derived fibrocytes being examples [24]. Collagen turnover and ECM 
remodeling is regulated mainly by matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs). Dysregulation of the balance between these 
may result in accumulation of collagen over time [21]. 
 
Anti-inflammatory drugs such as corticosteroids or immunosuppressive agents are in 
some cases able to relieve the symptoms but there is no drug that actually cures serious 
fibroproliferative disorders such as systemic scleroderma (SSc) or idiopathic 
pulmonary fibrosis (IPF). 
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Figure 1. Dysregulation of wound repair may lead to fibrosis. 
Wound healing: when epithelial or endothelial injury occurs, inflammatory mediators are released leading 
to an antifibrinolytic coagulation cascade triggering platelet activation and blood clot activation. 
Produced growth factors, cytokines and chemokines stimulate recruitment and proliferation of 
leukocytes. Leukocytes, such as macrophages and neutrophils contribute to eliminating tissue debris and 
invading organisms and production of cytokines and chemokines that are necessary for epithelial and 
endothelial cells that migrate to the centre of the wound. Lymphocytes and other cells secrete profibrotic 
cytokines such as PDGF, IL-13 and TGFβ leading to proliferation and differentiation of fibroblasts of 
different origin, or via epithelial/mesenchymal transition (EMT) into myofibroblasts. In the resolution 
phase myofibroblasts release extracellular matrix proteins and promote wound contraction. 
Epithelial/endothelial cells migrating over the basal layers regenerating the damaged tissue finalize the 
wound healing process [18].  
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1.3 Established anti-inflammatory therapies  
 
 Traditional NSAIDs and COX-2 inhibitors 
 
The most frequently used anti-inflammatory drugs are the NSAIDs (non-steroidal anti-
inflammatory drugs), and both aspirin and ibuprofen belong to this group. NSAIDs are 
used to treat acute and chronic pain and they are used also against chronic 
inflammatory disorders such as osteoarthritis. The therapeutic effects of these drugs 
include decreased vasodilation, oedema, pain and fever, and their mechanism of action 
is through inhibition of two enzymes, COX-1 and COX-2. This inhibition results in 
reduced formation of prostaglandins. 
 
NSAIDs also exhibit other important therapeutic effects, as they affect the synthesis of 
thromboxane, resulting in attenuated platelet aggregation. This property is double-
edged, on the one hand a benefit is that stroke and myocardial infarction is prevented, 
but on the other hand the risk for unintended bleeding may be increased. Accordingly, 
adverse advents are gastric bleeding following long-term use of COX1-inhibitors. In 
rare cases also the hepatic and renal functions are affected. 
 
In order to overcome the adverse advent of gastric bleeding, efforts have been made to 
develop selective COX-2 inhibitors. Unfortunately these were found to exhibit other 
more serious adverse effects such as stroke and heart attack caused by slightly 
increased levels of thromboxane. As a consequence, in 2004 Vioxx was taken out of 
the market [25]. At present Celebrex is still prescribed to patients with RA and 
osteoarthritis.  
 
Glucocorticosteroids 
 
Glucocorticoids (GCs) are broadly used as therapeutic agents in various inflammatory 
disorders including conditions such as asthma, RA, eczema and sepsis. GCs are 
derivatives of the natural endogenous anti-inflammatory steroid-hormone cortisol. The 
members of the glucocorticoid family, exemplified by dexamethasone and 
prednisolone, bind to the two glucocorticoid receptors (a and b) and mediate a spectrum 
of anti-inflammatory effects on cells expressing these receptors. The effects include 
inhibition of synthesis of cytokines, inflammatory mediators such as prostaglandins, 
transcriptional activity of COX-2, chemokines, complement factors and receptors of all 
these factors. 
 
The benefits of GCs are short term dampening of inflammation, vascular changes and 
limited immunosuppression but use is also associated with serious side effects at long 
term treatment; hypertension, thrombosis, changes in behavior and memory, 
gastrointestinal bleeding, osteoporosis and effect on renal function [26]. 
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Biologics 
 
The most recent contribution to the field of anti-inflammatory therapies is the use of 
monoclonal antibodies and antibody-like fusion proteins. Monoclonals against TNFα 
(infliximab) bind the cytokine with high affinity and this binding prevents TNFα from 
binding to its receptor.  Infliximab has revolutionized the treatment of patients suffering 
from RA, Crohn´s disease, ulcerative colitis and psoriasis. However, there are serious 
side effects of infliximab including increased risk of tuberculosis and other infections 
and worsening of preexisting heart disease. Etanercept, another type of TNF blocker, is 
a fusion protein consisting of the soluble human TNFα 2 receptor fused to the Fc 
fragment of human IgG1.  Etanercept has the function of a decoy receptor, eliminating 
TNFα from the circulation. It is used in treatment of RA and psoriasis and preliminary 
data shows that Etanercept is associated with less side effects than TNFα monoclonal 
antibodies [27]. 
 
Following the appearance of infliximab-based therapy, a number of other monoclonals 
have been introduced and these have effects on other inflammatory conditions. These 
include antibodies recognizing CD11a (efalizumab) as treatment of psoriasis and 
natalizumab recognizing the integrin α4β7 as treatment of MS and Crohn´s disease. 
Antibodies against the B-cell epitope, CD20 (rituximab) and CTLA4–immunoglobulin 
fusion protein (abatacept) that disrupts dendritic cell–T cell interactions, are other 
antibody or antibody like molecules shown to be useful for treatment of patients with 
RA. Today there are more than 30 different therapeutic monoclonal antibodies and 
fusion proteins that have been approved around the world of which the 15 best selling 
are shown in Table 1. Another 250 are in clinical trials focusing on treatment of 
malignancies, autoimmune and inflammatory diseases and infectious diseases [28-
30].  
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TABLE 1. The 15 best selling therapeutic monoclonal antibodies and fusion proteins 
with indications anti-inflammatory and autoimmune disease (www.pipelinereview.com 
April 2012). Rec-recombinant, RA-rheumatoid arthritis, TNFα-tumor necrosis factorα, 
IL-interleukin, RR MS-relapsing remittent multiple sclerosis, CTLA4-cytotoxic T 
lymphocyte antigen 4, CAPS- Cryopyrin-associated periodic syndromes, LFA3-ECD- 
Leukocyte function-associated antigen-1-extracellular domain 
 
Product Name  Target  Class of Compound  Indication  
 adalimumab  TNFα Rec fully human mab  RA 
 etanercept  TNFα Dimeric fusion protein of soluble TNF-R + 
CH2 and CH3 domains of Fc of Ig  
RA 
 infliximab  TNFα Rec chimeric IgG1 mab  RA 
 golimumab TNFα Rec fully human IgG1 mab, once monthly 
SC  
 RA; psoriatic 
arthritis;  
 certolizumab pegol TNFα PEGylated rec humanized Fab' fragment  Crohn's , RA  
 natalizumab α4/ß1/7 integrin  Rec humanized IgG4 mab  RR MS  
 omalizumab;  IgE  Rec humanized mab  Severe allergic 
asthma   
 abatacept  B7-1 (CD80) and 
B7-2 (CD86)  
Rec fusion protein of CTLA4+ Fc of IgG1 
(hinge, CH2 + CH3)  
RA and juvenile 
idiopathic arthritis  
 eculizumab Complement C5  Rec humanized (hybrid IgG2/4) full mab  PNH  
 tocilizumab  IL-6R  Rec humanized mab  RA  
 ustekinumab IL-12 (p40) and IL-
23  
Rec fully human IgG1 full mab (UltiMAb)  Psoriasis  
 canakinumab  IL-1 beta  Rec fully human IgG1 mab  CAPS, incl. 
Muckle Wells 
Syndrome  
 rilonacept  IL-1  Trap (2 IL receptor domains + CH2 +CH3 
of Fc)  
CAPS  
 belatacept  B7-1 (CD80) and 
B7-2 (CD86)  
(A29Y + L104E) point-mutated rec fusion 
protein of CTLA4+Ig  
Kidney 
transplantation  
 alefacept  CD2  Rec dimeric fusion protein of LFA3-ECD 
and CH2 and CH3 domains of Fc of IgG1 
for injection  
Psoriasis  
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Traditional DMARDs  
	  
DMARDs (disease-modifying antirheumatic drugs) are small synthetic compounds 
that not only reduce the symptoms of the disease but also actually slow down the 
progression and prevent tissue damage. The term DMARDs is derived from the first 
indication of e.g. methotrexate for RA. The drug has today various indications such as 
psoriasis [31] and systemic lupus erythematosus (SLE) [32]. 
 
 
1.4 New strategies to identify anti-inflammatory and 
antifibrotic agents  
 
New anti-inflammatory targets 
	  
As mentioned, considerable progress has been achieved in the treatment of 
inflammatory diseases during recent years. However, despite success, many patients 
and diseases are unresponsive to these new drugs and long-term treatment may also 
result in development of resistance to the drug. In addition, some of these new drugs 
have occasionally had deleterious effects in that the sensitivity to severe infections has 
increased. Other drawbacks with the new biopharmaceuticals are the sometimes very 
high costs and that they cannot be delivered orally. Thus, there is a need for new 
strategies to treat chronic and autoinflammatory diseases and there is a need for 
additional targets in the search for anti-inflammatory drugs [30]. 
 
A new generation of targets emerged during the 1990s was the cytokine superfamily, 
including TNFα, IL-1, interferons, growth factors of lymphocytes (IL-6, IL-2) and 
chemokines promoting activation, maturation and differentiation of cells involved in 
immunity and inflammation. Another group of targets are the toll-like receptors (TLRs) 
sensing microbial products or products of inflamed tissue. Downstream of these target 
molecules, several components of the signaling pathways such as transcription factors 
(NF-κB), kinases (p38, JNK, JAK/STAT) have been evaluated as new targets for 
development of anti-inflammatory drugs [33]. 
The NF-κB system of transcription factors regulates a large number of cytokines, 
chemokines, adhesion molecules and COX-2. Amongst these important activators of 
inflammation are the TNFα receptor family, the IL-1/TLR receptor family, the Nod-
like receptor family (NLR), IL-17 family and B and T cell receptors. A large number of 
regulating proteins are involved in regulation of the NF-κB pathway and the 
pharmaceutical industry are developing modulators targeting many of them. 
  
p38 kinase is known for stabilizing the mRNA of AU repeats occurring in 
inflammation-related genes including those coding for TNF and COX2. A few p38 
modulators are being evaluated as an anti-inflammatory treatment in clinical trials. 
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The JAK/STAT signaling pathway downstream hematopoietic cytokine receptors and 
interferons are involved in inflammatory disease. A JAK3 inhibitor, tofacitinib, has 
been developed and found to be efficacious in clinical trials for RA. It has recently been 
recommended for approval by the FDA arthritis advisory committee [34]. 
 
Moreover, immunosuppressors inhibiting the pathways leading to T-lymphocyte 
activation, such as IL-2, are interesting as targets. New calcineurin inhibitors prevent 
IL-2 production via deactivation of NFAT (nuclear factor of activated T cells). They 
have been approved for atopic dermatitis and have shown promising results in a 
clinical trial of psoriasis [35]. 
 
Another interesting T-cell-targeted therapy is FTY720, a synthetic drug targeting the 
sphingosine 1 phosphate receptor on T-cells, preventing egress of lymphocytes from 
the thymus and secondary lymphoid tissues is now approved for relapsing MS [36].  In 
addition, rapamycin analogues are being evaluated in clinical trial for RA and MS. 
They target the kinase mTOR in lymphocytes leading to inhibition of proliferation and 
IL-2 production [37]. 
 
Furthermore, IL-17 is a proinflammatory cytokine implicated in inflammatory disease. 
It is produced by certain subsets of T helper cells such as Th17, and mediates 
production of several proinflammatory cytokines and chemokines, e.g. IL-8, CCL2, IL-
1 and TNF. Brodalumab, an anti IL-17 receptor antibody has significantly improved 
plaque psoriasis in a phase II clinical study [38]. 
 
New antifibrotic targets 
 
Another therapeutic area with a large unmet medical need is the group of severe 
fibroproliferative diseases. Several growth factors, cytokines, lipids, and peptides are 
associated with fibrosis; TGFβ, tyrosine kinases (cAbl), CTGF, endothelin-1 (ET-1), 
interleukins such as IL-13 and IL-6, lysophosphatidic acid receptor 1 (LPA1) and Wnt.  
 
Accordingly various potential target groups are in evaluation for treatment of fibrotic 
disease, including i) antibodies against IL-13 and CTGF, a co-factor of TGFβ, are 
being evaluated in clinical trials (both in phase II) and results are awaited with interest, 
ii) an antibody against TGFβ as well as inhibitors of a tyrosine kinase (cAbl) down-
stream of TGFβ (imatinib) have so far shown lack of efficacy: iii) LPA1 is defined as a 
profibrotic target and clinical trials phase II will soon be initiated, iv) several existing 
T-cell targeted therapies are evaluated for the indication of fibrosis: v) rapamycin and 
an antibody against the IL-2 receptor (basiliximab), vi)  a fusion protein (abatacept) 
blocking of the co-stimulatory molecules B7 on antigen-presenting cells, and vii) two 
antibodies targeting B-cells, (rituximab and belimumab) may also be interesting to 
evaluate as antifibrotic therapies.  
 
Another group of potential targets are transcription factors such as STAT4 which is 
downstream of interferonγ and IL-2, T-bet, a regulator of the Th1 immune response, 
and AP-1 which is downstream of TGFβ and PDGF. 
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Moreover, several intracellular molecules may be interesting targets in the search for 
antifibrotic agents. Peroxisome proliferator-activated receptor gamma (PPARγ) is one 
example described to be down-regulated in biopsies obtained from scleroderma 
patients. Rosiglitazone, a PPARγ agonist, is already used as an insulin-desensitizing 
therapy in diabetes mellitus, which encourages evaluation as antifibrotic therapy in 
humans. Other examples are S100A4, an intracellular molecule signaling downstream 
TGFβ, and Notch, which are activated in leisonal skin of SSc patients.  
 
Finally, 5-hydroxytryptamine (5-HT, serotonin) and its receptor 5HT2b are interesting 
antifibrotic targets. 5-HT is released upon activation of platelets due to microvascular 
injury. 5-HT levels are increased in SSc patients and might be a link between vascular 
injury and fibrosis. 5-HT induces the synthesis of extracellular matrix proteins in 
dermal fibroblasts via the 5HT2b receptor and 5HT2b inhibitors prevented onset of 
experimental fibrosis and ameliorated established fibrosis. Results from a first small 
study in humans are awaited [39].  
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2 STRATEGIC AND CONCEPTUAL THINKING IN 
TARGETING CHEMOATTRACTANT 
RECEPTORS 
 
Another group of molecules that were explored as possible targets in late 1990s are the 
chemoattractants, mediators of cell recruitment in inflammation. Evidence linking 
chemoattractants and their receptors to different pathological states has been drawn 
from knockout and transgenic animal models, genetic association studies and 
expression studies in human disease tissue as well as experimental approaches with 
agonists and antagonists [40-44]. Beside their implications in infections and 
malignancies, they play important roles in inflammatory and autoimmune disorders 
such as atherosclerosis, RA, psoriasis, IBD as well as fibroproliferative diseases and 
many attempts are being made to modulate them in order to develop new drugs [12, 43, 
45-49]. 
 
2.1 Basic biology of chemoattractants and their receptors  
 
Chemoattractants and their receptors 
 
Cell migration is a key event of several physiological processes in multicellular 
organisms. It is a central process in embryonic development, wound healing, and 
immune surveillance, but also in many pathologies such as inflammation, fibrosis and 
malignancy. The driving force of migration is external signals and cells are moving 
directionally, guided by concentration gradients of such specific mediators, 
chemoattractants. Accordingly, the process is called chemotaxis [50, 51]. 
 
As a response to inflammatory stimuli, leukocytes migrate from blood through the 
endothelial cell layer to sites of inflammation. Migration is induced in response to 
concentration gradients of classical chemoattractants secreted from resident 
macrophages, destructed tissue or foreign invaders. The group of chemoattractant 
inflammatory mediators is heterogeneous with respect to chemical structure; the natural 
chemoattractants are proteins, peptides, phospholipids or lipids. N-formylated peptides 
(i.e., fMLF), defensins, C3a and C5a (fragments from the complement factors C3 and 
C5), leukotriene B4, platelet-activating factor (PAF) and in addition the large 
chemokine superfamily all belong to the group of classical chemoattractants [52]. 
However, several other endogenously expressed mediators e.g. cytokines and growth 
factors are attributed to have chemoattractant properties. In addition, recent research 
has led to the emergence of a new class of synthetic small molecule chemoattractants 
[53].  
 
With few exceptions chemoattractants induce cell migration through activation of 
receptors belonging to a family of structurally related so called seven transmembrane 
and Guanine nucleotide – binding Protein - Coupled Receptors (GPCR) expressed on 
the cell surface of leukocytes.  
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Chemoattractant receptors belong to the rhodopsin-like class A GPCR family. As 
mentioned these receptors have substantial similarities in that they form seven 
transmembrane helices (TM 1-7), enriched in hydrophobic amino acids (aa) and they 
all have an extracellular N-terminal and an intracellular C-terminal. They also have 
three intracellular (il1-3) and three extracellular loops (el 1-3) containing more 
hydrophilic amino acids.  A disulfide bond linking cysteine residues in extracellular 
loops 1 and 2 is also common. The TM3 region contains a preserved DRY (aspartate, 
arginine, tyrosine) motif and an aspartate residue in TM2, and these have been shown 
to be of importance for signaling from the activated receptor [40]. 
There are no signature residues or motifs common to all chemoattractant receptors 
that distinguish them from other types of GPCRs. However, some consensus features 
characterize them and distinguish them from other receptors of the GPCR family. 
They are shorter (approximately 350 aa) than other GPCRs, largely due to a very 
small i3 loop and a relatively short C-terminus. The short (16-22 aa) i3 loop is 
enriched in basic aa [54, 55] and the N-terminus is in most cases acidic [53, 56, 57]. 
 
Ligand binding induces conformation changes of the receptor catalyzing the switch 
from the GDP-state to the GTP-state of the G-protein resulting in dissociation of its α 
subunit from the βγ subunits and these transduce several cellular events. Activation of 
chemoattractant G-protein coupled receptors are in most cases coupled via one of the 
subgroups of the Gα subunits namely the Gαi, characterized by sensitivity to pertussis 
toxin [52]. Upon activation the receptor-expressing cell starts to move in the direction 
of the ligand source (Figure 2). 
 
Furthermore, chemoattractants contribute to the proinflammatory response via their 
receptors in a number of other ways. Ligand activated receptors induce important 
physiological processes such as production of reactive oxygen species (released to 
destroy/eliminate foreign microbes), secretion of proinflammatory mediators, gene 
transcription, receptor mobilization, and stimulation of cell adherence [52]. Moreover, 
emerging evidence suggests that chemoattractants are critical also for the 
immunomodulatory properties of the adaptive immune response. Accumulating 
evidence suggests that chemokines affect dendritic cell maturation, macrophage 
activation, B cell antibody class switching, and T cell activation [44, 58]. 
 
An additional attribute of chemoattractant receptors is that their signaling may mediate 
pro as well as anti-inflammatory effects (dual signaling). The chemoattractant receptor 
of interest may be expressed on both inflammatory and inflammatory-modulating cells. 
This is exemplified by the opposite effects of the on one hand CCR2 expressing 
inflammatory monocytes and on the other hand CCR2 expressing immuno down–
modulating regulatory T-cells in a collagen-induced arthritis model [59]. 
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Figure 2. Leukocytes expressing chemoattractant receptors transmigrate through the endothelial cell layer 
of the vessel wall in the direction of increasing concentrations of chemoattractants released from a site of 
inflammation. Ligand activated receptors induce important physiological processes such as 
degranulation/production of reactive oxygen species, secretion of proinflammatory mediators and T-cell 
polarization. 
 
In accordance with other GPCRs, chemoattractant receptors are phosphorylated and 
desensitized upon agonist binding and this process leads to an activation of the 
downstream intracellular signaling cascade required for receptor internalization and 
dampening of response of ligand binding. In addition, ligand induced activation of the 
receptor may also result in cross-desensitization of other receptors [60]. Desentitization 
of the receptor at high ligand concentration may result in the classic bell-shaped curve 
[61]. 
  
Some chemottractant receptors may be expressed exclusively in subtypes of leukocytes 
or in local tissues and certain cellular functions, such as recruitment of monocytes may 
be mediated by more than one receptor [41, 62, 63]. It is also well known that 
chemoattractant receptors are redundant, each receptor attracts more than one ligand 
and each ligand may interact with more than one receptor [43, 64].  
 
Chemokines and their receptors 
 
In contrast to other classical chemoattractants, the members of the chemokine family 
have conserved sequences and are structurally related [53]. The chemokine family 
includes 50 low molecular weight proteins (7.5-10 kDa, except for the 76 kDa 
membrane associated fractalkine). They are classified based on number and positions 
of conserved cysteine residues (C, CC, CXC and CX3C). Despite the fact that sequence 
identity between chemokines can range between 20 to 90%, their tertiary structures are 
highly conserved. The structure of chemokines comprises three distinct domains: (1) a 
highly flexible N-terminal domain, which is constrained by disulfide bonding 
between the N-terminal cysteine(s); (2) a long loop that leads into three antiparallel β-
pleated sheets; and (3) an α-helix that overlies the sheets (Figure 3) [65]. 
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Figure 3. Schematic representation of the three-dimensional structure of a C-C motif  chemokine [65]. 
 
The chemokines mediate their effects through 20 different receptors within the 
chemokine superfamily of GPCRs. Chemokine receptors are structurally related and 
distinguish from other GPCRs in that they have 2 disulfide bonds. Beside the disulfide 
bond between the first and second extracellular loop there is a second disulfide bond 
between the N-terminal and the third extracellular loop. The nomenclature of 
chemokine receptors follows the names of their ligands, C, CC, CXC and CX3C. The 
receptor family also includes decoy receptors (DARC, D6, CCX-CKR) that take part in 
chemokine clearance [40].  
 
Furthermore, chemokine receptors can form homo-, hetero- and even oligomeric 
structures with other structurally related receptors and influence each other’s signaling. 
The different oligomeric structures are controlled by the expression levels of the 
different receptors and the presence of their ligands [66].  
 
To add further complexity, chemokines do not only bind to receptors on the leukocyte 
surface but also to glycosaminoglycans (GAG) exposed on endothelial cells and 
deposited in the extra cellular space. Chemokines oligomerize on the endothelial cell 
surface to which leukocytes are attracted [66] and in many cases, oligomerization is 
critical for their proper function in vivo [67]. Dimerization, oligomerization and binding 
to GAGs may also protect chemokines from proteolytic degradation [68]. 
 
 
2.2 Targeting chemoattractants and their receptors in drug 
discovery 
 
Chemoattractants and their receptors are important regulators of the innate as well as 
the adaptive immune response and dysregulations may lead to pathologies. These 
receptor-ligand pairs control and organize trafficking and functional activation of 
leukocytes in health and disease in processes that are not yet completely understood. 
Expression and stimulation of chemoattractant receptors is very much dependent on the 
homeostasis of the tissue and the influence of different pathologies. Although large 
efforts have been made and different strategies have been validated for targeting 
chemoattractants and their receptors, rather few drugs have been approved on the 
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market. In retrospect, targeting chemoattractant receptors has shown to be a rather 
challenging task with the risk for many pitfalls as the biology of this target group is 
very complex [41, 42, 69].  
 
Several approaches are used in drug discovery to modulate the effects of 
chemoattractants and their receptors. They include the development of small molecule 
agonists/antagonists, modification of peptide ligands, monoclonal antibodies (Mab) and 
Fab fusion proteins. 
  
Screening for small molecule receptor modulators  
	  
One strategy for targeting the chemoattractant receptors is to screen for small 
compound receptor agonists or antagonists using high-throughput screening (HTS) of 
small compound chemical libraries. Using this rational large-scale approach many 
thousands of compounds can be screened resulting in a large spectrum of receptor 
ligands exhibiting different sizes, receptor affinities, functional responses and 
biophysical properties such as solubility and bioavailability. 
 
As the primary selected screening hits do normally not fulfill all the requirements of a 
lead compound, a lead optimization process follows the primary screening, a process 
that is in many cases time and resource consuming. Large efforts are normally 
required to develop a new chemical entity and besides efficacy, parameters such as 
absorption, distribution, metabolism, excretion and toxicity (ADMET) need to be 
taken into account [70]. 
 
On the positive side is the production costs of small molecules which are normally 
more favorable compared with those for biologics. In addition, small molecule 
compounds have a greater potential of being orally available than biologics which are 
often susceptible to proteolytic degradation. An interesting opportunity is that small 
compounds may be cell permeable and, in similarity with cyclosporine and COX 
(cyclooxygenase) inhibitors, can act within the cell downstream of the surface 
receptor [69].  
 
Small molecule high-throughput screening strategies of GPCRs are either based on 
functional cellular assays or cell-free biochemical assays, such as binding assays. A 
binding assay can be performed in a very rational way using homogenous membrane 
preparations of the receptor-expressing cell and a radiolabeled ligand. The downside 
of this approach is that only ligand affinity is measured meaning that receptor 
agonists are not distinguished from antagonists or inverse agonists. A binding assay is 
a good complement in the evaluation of hits, thus indicating if the selected compound 
actually binds to the receptor or unspecifically to the surface or is taken up by the cell 
interacting intracellularly [71].  
 
If the screening strategy is based on a functional cellular assay, other considerations 
need to be taken into account. The conventional way of functionally screening 
GPCRs is using modification of G-protein dependent second messengers such as 
calcium release or cAMP accumulation. These two are well established “high-
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throughput compatible” read-outs. However, also other general assay concepts have 
recently been developed such as beta-arrestin based functional assays and whole cell 
label free assays [71]. 
 
Calcium release screening makes it possible to screen thousands of compounds within 
a short time using high-throughput equipment like a FLIPR (fluorometric imaging 
plate reader). The signal to noise ratio is large and hit selection is a relatively 
straightforward process. Traditionally, transfected cell lines such as human 
embryonic kidney cells (HEK293) or chinese hamster ovary cells (CHO), over-
expressing the receptor of interest have been used. If the ligand stimulated transfected 
cell line does not respond with calcium release, complementary Gα proteins, such as 
Gα16, may be co-transfected to shift the agonist induced response to calcium release 
[72]. It is also possible to use transformed or tumor cell lines that endogenously 
express the protein of interest. One such example is the THP-1 cell line (human acute 
monocytic leukemia cell line) expressing CCR2B. In addition, the use of primary 
cells is increasing, as it is a more relevant in vitro model. 
 
All the strategies discussed are associated with their specific advantages and 
disadvantages and one has to be aware of the different interpretations of the responses 
that can be made. First of all, the relevance of the functional response needs to be 
considered. The most conventional approaches such as measuring modified calcium 
release in transfected cell lines may not reflect modifications of the most relevant 
disease-related cellular event. If it is possible one should consider the use of a method 
that actually makes it possible to select compounds modulating the functional 
response of interest [73].  
 
Using primary cells may however be associated with other problems such as low 
signal to noise ratio. Isolation of primary cells is also resource consuming and the 
preparations may differ depending on individual status of organ or blood donors or on 
the animal used. It is thus an advantage to use a limited number of cells/organs both 
for the primary screen and the hit confirmation. 
 
 
Biologics 
 
The natural activation of many of the chemoattractant receptors involves the 
interaction between large macromolar ligand and receptor molecules and simulation 
of that interaction with molecules of a limited size may be associated with difficulties 
[69]. It has been proved relatively difficult to identify small molecule 
blockers/inhibitors of chemoattractant receptors. One reason may be that 
chemoattractants, in particular chemokines, are large molecules and use other types of 
binding pockets than other smaller GPCR ligands such as monoamines. In addition, 
chemokine receptors may have more than one binding pocket as they normally attract 
more than one type of chemokine. Consequently, it may not be enough with one 
compound that interacts with only one of the binding sites to efficiently block the 
receptor [42]. Accordingly, other approaches may be relevant for the development of 
chemokine receptor antagonists. 
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A mechanism used by the immune system to regulate and fine-tune the inflammatory 
reaction and chemokine activity is to modify ligands [74]. Chemokine variants may 
be formed through polymorphism at the gene level or through post-translational 
modifications such as proteolytic truncations, glycosylations, deamination and 
citrullination. CXC- as well as CC-chemokines may also lose activity through 
proteolytic degradation/truncation [74]. According to this, another approach to target 
chemoattractant receptors is to generate modified peptide ligands. This chemokine 
engineering strategy opens many possibilities and one big advantage compared to 
small molecule library screening is that the starting molecule is a bioactive high-
affinity molecule. One example is truncated CCL2 (1,9-76), described in 4.3 that is 
transformed from a potent CCR2 agonist into an antagonist. However, it is clear from 
the work performed so far that chemokine/receptor axes have unique properties and 
no general rules for how to transform an agonist into an antagonist have been 
established [75-77]. This strategy also has other limitations in that chemokines are 
relatively large and complex molecules that are sensitive to protelytic degradation and 
relatively rapidly cleared from the circulation. To overcome this issue, biologics such 
as small ligand peptides or soluble receptors are fused to a stabilizing partner protein 
e.g. an antibody-derived Fc fragment. 
However, the production and purification of large biomolecules using recombinant 
technology is complex and expensive unless the size of the molecule can be reduced. 
 
An interesting approach to modify the activity of chemokine receptors is to develop 
non-GAG binding chemokines. These peptide ligands will not be sequestered via 
GAG binding at the cell surface but will stay in the circulation for a longer time than 
conventional chemokines. They will neither contribute to the formation of the solid-
phase concentration gradients leading to chemotaxis of leukocytes. These modified 
chemokines mediate their anti-inflammatory actions by homologous and heterologous 
desensitization of the receptors [60].  
 
A third alternative to modulate the reactivity is to neutralize either the 
chemoattractant or the receptor with an antibody. However, few therapeutic 
antibodies against chemoattractants have yet been approved for clinical use and so far 
no antibody targeting a GPCR has been approved. A possible reason is that GPCRs 
are well integrated in the cell membrane and are not exposed enough to trigger a 
strong immunogenic response [78]. 
 
General concerns about targeting chemoattractant receptors 
 
There are general issues in common for all these approaches. Selectivity of the target is 
a relevant issue in all drug discovery, not least in the development of drugs with effects 
on chemoattractants or their receptors. The fact that chemoattractant receptors 
preferably are studied in vitro in primary cells expressing multiple chemoattractant 
receptors, subgroups of sequence and structurally related receptors, may complicate the 
analysis of selectivity. The use of relevant tools in the form of specific agonist and 
antagonist is thus essential. 
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Another important aspect is the cross species activity of the receptor modulator of 
interest. The compound may be selective for the human receptor, activating e.g. the 
murine receptor weakly or not at all. Human chemoattractant receptors often have two 
or more murine orthologues and the identity of the dominating one in relation to the 
human origin is not always clear. This is clearly illustrated when looking at the FPRs; 
there are three human FPR receptors whereas the number in mice far exceeds this 
number [79]. 
It may also be the other way around. CXCR1 is the main neutrophil chemoattractant 
receptor in human for recruitment of neutrophils by the cytokine IL-8. The gene coding 
for CXCR is lacking in mice that instead use CCR1. Consequently, diseases involving 
neutrophils and macrophages are sometimes difficult to validate in mouse models [62]. 
This is one of the most challenging issues in development of new drugs and so far there 
is no ideal solution. One strategy to compensate for this is to perform ex vivo studies in 
human primary cells and the human tissue of interest [62, 69].  
 
Two examples of anti-inflammatory drugs targeting chemoattractant 
receptors on the way to the market 
 
CCR9 is central for migration of immune cells to the intestine. Its ligand CCL25 is 
expressed at the mucosal surface of the intestine and is elevated in intestinal 
inflammation (IBD, Crohn´s disease and ulcerative colitis). A small molecule 
antagonist (CCX282) has been developed which inhibits CCR9-mediated cell 
recruitment in a murine colitis model. The compound is being evaluated (phase III) 
for the indication of Crohn´s disease [80]. 
 
One of the chemoattractant axes more extensively studied and explored by the 
pharmaceutical industry is the C5-C5a receptor axis. Targeting the C5-C5a receptor 
axis is an appropriate example that illustrates most of the different strategies applied 
in targeting chemoattractants and their receptors for the development of anti-
inflammatory drugs. C5 is part of the complement system of the innate immunity and 
activation leads to cleavage of C5 to C5a and C5b that subsequently form the 
terminal complement complex (C5b-9). C5a mediates its proinflammatory effects via 
two GPCR receptors, CD88 and C5L2. CD88, a G-protein coupled receptor, is well 
established as a central mediator of proinflammtory events in host defense against 
foreign microorganisms as well as in chronic inflammatory diseases. CD88 is 
expressed on a wide variety of cells and activation by C5a mediates several 
proinflammatory cellular events. The C5-C5a receptor axis has been implicated in 
several large inflammatory disorders such as sepsis, arthritis, irritable bowl disease, 
ischemia reperfusion and neurodegenerative diseases. 
Several attempts have been made to neutralize C5 and C5a with monoclonal 
antibodies. To date there is one anti-C5 antibody, eculizumab (Alexion 
Pharmaceuticals), a humanized antibody approved for treatment of paroxysmal 
nocturnal hemoglobinuria (PNH), a serious hematologic disorder. As eculizumab is a 
humanized antibody there is a potential risk for immunogenic reactions in patients 
upon long term treatment and a second generation of fully human anti-C5 antibodies 
are in development. 
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Another approach to target the C5-C5a receptor axis is the development of CD88 
receptor antagonists. Bearing in mind that the 8 residues of the C-terminal of C5a 
retain the activity of CD88, truncated high affinity peptide receptor antagonists have 
been developed. These compounds have demonstrated efficacy in animal models and 
some of them have been evaluated in clinical trials. Unfortunately so far these trials 
have been halted for different reasons; lack of efficacy in patients, off-target activities 
with other receptors, lack of cross species activity or that they were potentially 
immunogenic.  
In addition, several non-peptide small molecule C5a antagonists have been 
developed. The development of these types of antagonists has been halted for various 
reasons such as lack of cross-species activities, toxic effects, low efficacy and lack of 
oral activity. One compound, the orally active CD88 antagonist CCX168, has 
demonstrated efficacy in a model of anti-neutrophil cytoplasmic autoantibody 
(ANCA) disease and has now entered clinical trials (phase II). Finally, a series of 
anti-CD88 antibodies were reported, e.g. Neutrazumab, they are so far in preclinical 
development [45].  
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3 THE FPR FAMILY-A GROUP OF 
MULTIFACETED TARGETS OF ANTI-
INFLAMMATORY THERAPEUTIC INTEREST  
 
3.1 Basic biology of FPRs  
 
Unlike other leukocyte chemoattractants, N-formyl peptides could originate from 
either an endogenous source, such as the mitochondrial proteins of ruptured host 
cells, or an exogenous source, such as the proteins/peptides of invading pathogens. N-
formyl peptides mediate their effects via the formyl peptide receptor family (FPR) of 
GPCR receptors. The human FPRs constitute three members whereas the family has 
seven members in mouse [81]. The human family of these receptors was cloned in 
1990 [82] and in 2010 the nomenclature of the receptors, FPR1, FPR2 and FPR3, was 
revived from the previously named FPR, FPRL-1 and FPRL-2 [79]. These three 
receptors display large sequence homology and accordingly exhibit pronounced cross 
reactivity with several ligands. Both neutrophils and monocytes/macrophages have the 
ability to recognize and respond to a large number of molecules that bind FPRs and 
serve as “danger signals”. Emerging evidence shows that agonists and antagonists of 
these receptors regulate a large number of biological functions [43, 83]. 
 
The most extensively studied of the three receptors is FPR1 [5, 84] which is the high 
affinity receptor of formyl-methionyl-leucyl-phenylalanine (fMLF) and the first 
neutrophil GPCR to be cloned and sequenced [82]. fMLF was the first structurally 
defined chemoattractant, a bacterial produced peptide that triggers a variety of 
proinflammatory biological activities in neutrophils. fMLF induces calcium release, 
protein kinase cascades and membrane polarization at low nanomolar concentrations, 
while release of superoxide is more notable at higher nanomolar concentrations [4, 
83, 85-87]. 
 
Beside fMLF, FPR1 binds with high affinity and is activated by a large range of ligands 
such as virus-derived peptides e.g. T20/T21 (HIV-1 gp41) [43], the synthetic peptide 
tool, WKYMVm [88] and non-formylated peptides [83, 89]. 
 
Gradients of receptor ligands induce migration of FPR expressing neutrophils from 
blood into inflamed and infected tissue where they exert antibacterial effector 
functions such as degranulation and upregulation of integrins. The granules in mature 
neutrophils contain a variety of proteins and can be classified as peroxidase-positive 
and peroxidase-negative. The peroxidase-positive azurophilic granules are those 
carrying anti-microbial proteases and myeloperoxidase (MPO). Upon neutrophil 
stimulation, azurophilic granules fuse with the phagosome and release their contents 
thereby exposing the ingested microbe to toxic agents resulting in bacterial death [6]. 
The enveloping membranes of the peroxidase-negative granules contain a variety of 
functionally important membrane proteins such as complement receptor 3 
(CR3/CD11b), the NADPH oxidase component flavocytochrome b558, and FPR1. 
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These membranes fuse with secretory vesicles and the plasma membrane and 
constitute reservoirs of important integral membrane proteins ready to be recruited to 
the surface of activated neutrophils [90]. 
 
Associated with degranulation of stimulated neutrophils is the “phagocyte respiratory 
burst”, a coincidental abrupt increase of oxygen consumption, leading to production 
of toxic reactive oxygen species (ROS). This is one of the antibacterial strategies used 
by neutrophils in host defense, and responsible for this cellular event is the activation 
of the NADPH oxidase enzyme complex. NADPH oxidase is segregated into the 
membrane and cytosol in resting neutrophils; the heterodimer of gp91phox and p22phox, 
parts of the flavocytochrome b558, is localized in a membrane while the other 
components, p47phox, p67phox and p40phox, are found in the cytosol of resting cells.  
Upon activation p47phox, p67phox and p40phox are translocated to the membrane where 
the NADPH oxidase is finally assembled. Active NADPH oxidase in the membrane 
transfers electrons from the NADPH in the cytosol across the extracellular membrane 
where superoxide anions are produced in the presence of molecular oxygen (Figure 
4). Superoxide can also be produced in intracellular compartments where it 
dismutases to H2O2 or reacts with other oxygen species generating a number of 
different oxidants [6]. 
 
               
 
 
Figure 4. Active NADPH oxidase in the membrane transfers electrons from the NADPH in the cytosol 
across the extracellular membrane where superoxide anions are produced in the presence of molecular 
oxygen [91]. 
 
Furthermore, FPR signaling has been reported to regulate the survival of infiltrating 
cells within the site of inflammation. Proinflammatory and prosurvival formylated 
peptides and endogenous serum amyloid A (SAA) and fMLF compete with pro-
apoptotic, proresolution factors such as annexin A1 and LXA4 described in 3.2 [92]. 
 
Signaling via FPR1 is regulated by two processes, receptor desensitization and 
agonist-induced internalization. Desensitization occurs either by direct ligation or 
following activation of similar GPCRs. After initial activation of FPR1 with fMLF, 
the receptor rapidly reduces its responses to secondary stimulation with the same 
agonist (homologous desensitization). FPR1 is also desensitized via ligation of other 
GPCRs (heterologous desensitization) such as C5aR or CXCL2/IL-8, in a 
concentration-dependent manner. FPR1 is quite highly placed in the hierarchy of 
GPCR cross talk, and it can downregulate a variety of GPCRs more efficiently than 
the other way round. The mechanism of receptor internalization has been shown to be 
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independent of β-arrestin but is suggested to depend on the conformational 
differences of each ligand-FPR1 complex [43].  
 
 
3.2 FPR2 - a chemoattractant receptor with dual functions 
 
The structures of FPR1 and FPR2 are very similar and there is considerable 
promiscuity across these receptors. However, FPR2 is an unusual receptor as it is 
activated by a large number of exogenous and endogenous ligands of different 
chemical structures (peptides, lipids and small molecules), capable of inducing pro as 
well as anti-inflammatory responses (Figure 6). The signal transduction is therefore 
complex and far from fully investigated. However, the intracellular parts of FPR1 and 
FPR2 have close homology in their intracellular domains and accordingly, the 
proinflammatory cellular responses exhibit large similarities between the two 
receptors. FPR2 is a low-affinity receptor of fMLF, that together with amyloidogenic 
peptides (beta-amyloid42 and acute-phase protein SAA), HIV-envelope gp120, the 
truncated form of the ß-chemokine, CKß 8-1 and the synthetic peptide WKYMVM, 
induce proinflammatory actions in neutrophils such as NADPH oxidase activation and 
degranulation. In addition, the interaction between SAA and FPR2 was reported to 
induce NF-κB activation and IL-8 secretion by neutrophils [93]. 
 
As mentioned, FPR2 is also described to exhibit significant anti-inflammatory and 
proresolution responses in vitro and in vivo. These actions were mediated by 
endogenous human peptides such as annexin A1 and synthetic derived peptides such as 
Ac2-26 [94], humanin and one of the most extensively studied FPR2 agonists, the 
eicosanoid lipoxin A4 (LXA4). 
 
Lipoxin A4 
 
LXA4 and LXAB (Figure 5) are structurally and functionally distinct amongst the 
lipid-derived mediators in that they possess a trihydroxytetraene structure and primarily 
mediate anti-inflammatory activities [95, 96]. It was shown by displacement of 
radiolabeled LXA4 that LXA4 binds with high affinity and selectivity to the FPR2 
receptor on both primary neutrophils and FPR2-transfected CHO cells [79]. In addition, 
the two FPR2 ligands, LXA4 and WKYMVM were shown to inhibit the calcium 
release signal elicited by each other suggesting that they activate the same receptor in 
neutrophils, FPR2 [97]. However, it is important to recognize that conflicting data has 
recently been reported, suggesting that LXA4 does not act via FPR2 in neutrophils 
[98]. Furthermore, LXA4 was also reported to bind to the nuclear aryl hydrocarbon 
receptor [99] and the leukotriene receptors [100]. 
 
Upon proinflammatory stimulation, in particular by PGD2 and PGE2, lipoxins are 
synthesized from arachidonic acid via cellular and transcellular interactions by two 
major routes involving leukocyte 5-lipooxygenase and 12-lipooxygenase [101-103]. 
Aspirin-triggered lipoxin A4, (ATL) (Figure 5), is a stable lipoxin-derivative with 
similar functions synthesized via an acetylated form of COX-2 [103]. Intake of aspirin 
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(acetyl-salicylic acid) encourages the acetylation of COX-2 and may be one the 
therapeutic actions of aspirin. 
 
                       
      LXA4                                         LXB4                                       ATL                             
 
Figure 5. Structures of the eicosanoids LXA4, LXAB and ATL. ATL is the enantiomer of LXA4, 
synthesized by an acetylated COX-2.  
 
LXA4 and ATL have been reported to exhibit very specific anti-inflammatory 
properties both in vitro and in vivo. These effects have been extensively described 
during the last 15 years [43, 104, 105] and LXA4 and ATL were described as mediators 
with “multifaceted” anti-inflammatory and proresolving activities. LXA4 and modified 
stable analogues were described to mediate several cellular events in neutrophils such 
as inhibition of cell adhesion, transmigration and cytokine secretion [106-109]. They 
have also been described to prevent ROS generation such as the formation of NO and 
ONOO-  by neutrophils [109-115]. 
 
Moreover, LXA4 and ATL have been described to play a major role in the resolution 
of inflammation, together with the recently described resolvins and protectins, and 
these effects have been suggested to be mediated in part through binding to FPR2 [116, 
117]. Resolution of inflammation is the process leading to homeostasis and restored 
tissue. Traditionally it was believed that resolution was a passive process, a result of 
withdrawal of proinflammatory events. Emerging evidence points out that resolution is 
a strictly regulated active process that already starts in the induction phase of the 
inflammation. 
 
Lipoxins promote resolution by stimulating adherence and monocyte chemotaxis to 
site of inflammation without causing degranulation or release of reactive oxygen 
species [118]. It has been shown in vitro that lipoxin stimulates clearance of apoptotic 
neutrophils by monocyte-derived macrophages in a nonphlogistic manner [117, 119-
122]. 
 
Consistent with a role for lipoxin promoting the resolution of inflammation are the 
observations that lipoxin-stimulated phagocytosis is associated with increased 
transforming growth factor-ß1 (TGF-ß1) and IL-10 release from macrophages, which 
further activates proresolving loops, as well as a decrease in the proinflammatory 
chemokines IL-8 and monocyte chemoattractant protein-1 (MCP-1/CCL2) release 
[120, 123]. Moreover, there are several examples demonstrating that impaired lipoxin 
synthesis is correlated with a more chronic inflammatory phenotype in vivo [124-
126]. 
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Figure 6. Activation of FPR1 leads to proinflammatory responses in neutrophils. Differential ligand-
dependent signaling of FPR2 leads to either proinflammatory or anti-inflammatory responses.    
 
 
3.3 Clinical implications of the FPR receptors and their 
ligands  
FPR1 as well as FPR2 have been associated with several inflammatory and 
autoimmune disorders such as peridontitis (FPR1), allergy, Alzheimer’s disease and 
RA (FPR2). Furthermore, ligands of FPR2, mediating proinflammatory as well as anti-
inflammatory actions, are associated with inflammatory diseases such as RA (LXA4, 
annexin A1 and SAA), Alzeimer (annexin A1) and asthma, peridontitis, and colitis 
(LXA4) [43, 127-131].  
Thus, receptor modulators of FPR1 and FPR2 as well as ligand mimetics may be of 
therapeutic value in a wide range of inflammatory diseases. One example is CGEN-
855A, a synthetic FPR2 peptide agonist that was reported to exhibit efficacy in various 
acute in vivo models [132]. Moreover, several small molecule FPR2 agonists, such as 
the pyrazolone (compound 43) and FPR2 antagonists, quinazolinones (e.g. Quin-C7), 
have been developed by screening small molecule libraries. These compounds were 
reported to exhibit efficacy in established acute in vivo models such as inhibition of 
arachidonic-induced ear swelling in mice [133, 134]. 
Finally, one approach has been to develop lipoxin mimetics with improved metabolic 
stability. Several lipoxin analogues have been designed that have demonstrated 
comparable efficacy in vivo [135]. This approach has been used to develop 3-oxa-
LXA4 analogues with potent anti-inflammatory profile and oral activity, that 
promoted the resolution of an established colitis model in mice [127]. 
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3.4  Receptor-specific tools 
 
As mentioned, the proinflammatory cellular responses downstream FPR1 and FPR2 
exhibit large similarities between the two receptors. Investigations aimed to clarify 
differences in the downstream signaling from these receptors require tools in terms of 
receptor-specific agonists and antagonists. In the present study, fMLF, WKYMVM, 
cyclosporine H, WRWWWW and PBP10, previously described, were used as receptor-
specific tools (Table 2). 
Recently an inhibitor of FPR2 signaling, PBP10 was described. PBP10 is a gelsolin-
derived peptide of 10 residues, conjugated to rhodamine B and has shown to be cell 
permeable in fibroblasts, platelets, melanoma cells and neutrophils. It is reported to be a 
strong PIP2 (phosphatidyl 4,5-biphosphate)-binding peptide and prevents chemotactic 
peptide stimulated actin assembly in platelets and neutrophils [136]. In detailed studies 
in neutrophils it was shown that PBP10 had a strong preference for inhibition of 
WKYMVM-stimulated over fMLF-stimulated signaling [137].  
 
Ligand FPR1 FPR2 Reference 
Agonists    
fMLF Kd=1 nM  
EC50=75 nM (ROS 
secretion) 
Kd=1 µM [95] 
[88] 
WKYMVM Unresponsive (calcium 
release) 
EC50=2 nM (calcium 
release) 
EC50=75 nM (ROS 
secretion) 
Kd=160 nM 
[88] 
WKYMVm 1 nM (calcium release) 1 pM (calcium release) [83] 
Antagonists/Inhibitors    
cyclosporin H IC50=120 nM (ROS 
secretion elicited by 20 
nM fMLF ) 
IC50 > 10 µM (ROS 
secretion elicited by 20 
nM WKYMVM) 
[138] 
WRWWWW IC50>5 µM (ROS 
secretion elicited by 20 
nM fMLF 
IC50 > 200 nM (ROS 
secretion elicited by 20 
nM WKYMVM) 
[138] 
PBP10 No inhibition of calcium 
response elicited by 
fMLF at 1-100 nM by 
stimulation with 1 µM 
PBP10 
Calcium response 
elicited by 100 nM 
WKYMVM is reduced 
to 50 % by stimulation 
with 1 µM PBP10 
[136, 137] 
 
Table 2. Receptor-specific tools were used in present study to determine receptor-specific activation of 
FPR1 and FPR2 (paper I and II). 
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4 TARGETING CCL2 AND ITS RECEPTOR CCR2 
IN SEARCH OF ANTI-INFLAMMATORY AND 
ANTI-FIBROTIC DRUGS 
4.1  Basic biology of the CCL2/CCR2 axis  
 
CCL2 (MCP-1-monocyte chemoattractant protein-1) was the first human C-C 
chemokine described and it belongs to a family with at least four members, CCL8 
(MCP-2), CCL7 (MCP-3) and CCL13 (MCP-4). CCL2 is a potent chemoattractant for 
monocytes but also for T-lymphocytes and natural killer (NK) cells, recruiting these 
cells to sites of inflammation. CCL2 triggers the firm adhesion of monocytes to the 
vascular endothelium as well as migration through the vessel wall [65]. CCL2 may also 
be a key mediator of recruitment of monocytes from the bone marrow into the blood 
stream during homeostasis and with increased activity during inflammation [139]. The 
major source of CCL2 is hematopoietic cells, mainly monocytes and macrophages. 
CCL2 is also produced by endothelial and epithelial cells, fibroblasts, smooth muscle 
cells, astrocytes, mesangial cells and microglial cells.  
 
Human CCL2 is a peptide of 76 amino acids some of which have been identified as 
critical for biological activity. The N-terminal residues have been shown to be 
important for receptor binding, induction of monocyte migration, and receptor 
desensitization [140-142]. It has been shown that the full-length CCL2 forms 
homodimers and some of the critical residues for dimerization were also localized in 
the N-terminus [140, 143]. CCL2 is secreted in two predominant forms of 9 and 13 
kDa, respectively, differing in O-glycosylation sites. There is no difference in the 
biological activity between the two forms.  
Expression of CCL2 is regulated at the transcriptional level by cytokines and growth 
factors such as TNFα, Interferonγ, PDGF as well as infectious agents and stress factors 
such as reactive oxygen species. Many of these responses are signaled via the 
proinflammatory factor NF-κB [142, 144].  
 
CCL2 mediates its effects via CCR2, a GPCR with many similarities to those described 
above. There are two splice variants of the human CCR2 receptor, CCR2A and CCR2B 
that differ only in the C-terminus. CCR2A is the major isoform expressed on 
monocytes and vascular smooth muscle cells while CCR2B is expressed on monocytes 
and activated NK cells [65]. 
 
CCR2, the main receptor for CCL2, has dual roles as it mediates both pro and anti-
inflammatory activities. The proinflammatory function is dependent on monocytes, 
APCs and T-cells, while the anti-inflammatory function is dependent on receptor 
expression in regulatory T-cells [65]. Moreover, there is emerging evidence indicating 
that the CCL2/CCR2 axis also is involved in T-cell immunity. CCL2 is associated with 
Th2 cell-mediated responses and has shown to induce the polarization of Th0 to Th2 
cells in mice, possibly via upregulation of the Th2 cytokine IL-4 [65]. 
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The murine CCR2 (JE receptor) shows 80% amino acid sequence identity with CCR2B 
[145]. In murine models CCL2 is corresponded with murine CCL2 (JE) that has a 55% 
identical amino acid sequence for the first 76 amino acids, but has also an extension of 
49 amino acids in the C-terminus. Human CCL2 and JE have similar chemoattractant 
activity and thus they are structural and functional homologues [146]. Another agonist 
of the JE receptor, less potent, is CCL12 that shows 63 % sequence identity with 
human CCL2 [147].  
 
 
4.2 Clinical implications of the CCL2/CCR2 axis  
 
The CCL2/CCR2 axis is a major player in several pathologies associated with 
monocyte recruitment and it has been implicated in many diseases involving 
macrophages [65]. Mice genetically deficient in CCR2 as well as its ligand CCL2, 
exhibit reduced monocyte recruitment in disease models of peritonitis, tuberculosis and 
atherosclerosis [148]. Moreover, increased levels of CCL2 have been detected in 
synovial fluid from patients with RA, in bronchial epithelium of patients with 
idiopathic pulmonary fibrosis and in inflammatory skin diseases. CCL2 is also found in 
increased levels in macrophage-rich regions of atherosclerotic lesions and chronic acute 
hepatitis [149, 150]. 
 
The major role of the CCL2/CCR2 axis in inflammatory disease has many implications 
that make this receptor/ligand pair interesting as targets for new therapeutic drugs. 
Antagonizing the CCL2/CCR2 axis has been evaluated in several established animal 
models such as experimental autoimmune encephalomyelitis (EAE an in vivo model for 
MS), collagen-induced arthritis (CIA an animal mode of rheumatoid arthritis), 
bleomycin induced fibrosis, and in CCL2-/- and CCR2-/- knockout models. Results 
using all these models demonstrate both beneficial and non advantageous effects 
indicating a complex biology of blocking the CCL2/CCR2 axis using anti-CCL2 and 
anti-CCR2 monoclonal antibodies, modified peptide ligands and small molecule 
receptor antagonists. None of the evaluated agents have so far been approved, some of 
them have advanced as far as to a clinical phase II trial [150]. 
 
A humanized anti-CCR2 monoclonal antibody, MLN-1202, has been evaluated in 
clinical trials for MS, RA and atherosclerosis (phase II trials). The clinical outcome in 
the MS study was a small therapeutic effect (reduction of GD enhancing lesions) but 
unfortunately, there was no effect demonstrated in RA. A significant effect was 
observed in the clinical trial of atherosclerosis such as reduced CRP levels in patients 
with increased risk for atherosclerosis [150]. 
 
A small molecule CCR2 antagonist, MK0812, was evaluated in clinical trials with MS 
and RA patients (phase II) where no therapeutic effects were observed [150, 151]. 
Moreover, a study with a human monoclonal antibody, ABN912, targeting CCL2, was 
evaluated in a study with patients with active RA [152]. The clinical outcome was 
confusing. There was no therapeutic effect, rather the disease was aggravated in 
patients administered the highest dose. An explanation was suggested to be related to 
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the increased serum levels of CCL2 observed shortly after administration of the 
antibody. This was explained by immobilization of bound CCL2 and slow clearance of 
the CCL2-antibody complexes [150].  
 
Development of modulators of the CCL2/CCR2 axis continue, but it is now focused on 
other therapeutic indications such as diabetes associated disorders [153, 154], 
neuropathic pain [155, 156], tumor diseases [142, 157, 158] and fibrosis [159-161] 
(paper III and IV). 
 
 
4.3 7ND - a modified peptide antagonist 
 
As mentioned the CCL2/CCR2 axis has been addressed with different approaches such 
as small molecule CCR2 inhibitors and antibodies against the ligand as well as the 
receptor. An additional strategy, discussed previously (page 19) is to use modified 
peptide ligands. The truncated variant of human CCL2 (1, 9-76), lacking amino acids 
2-8, also named 7ND is an example of a peptide ligand agonist that is manipulated to 
obtain antagonistic properties. 7ND was first designed and characterized by Gong et al 
[162] and has been shown to have therapeutic effects in several animal in vivo models 
related to fibrosis and inflammatory diseases [163-167]. Interestingly, in all described 
examples, human 7ND was administered by gene transfection ensuring continuously 
transcribed protein. The reason may be that 7ND has a relatively short half life time in 
plasma and continuously expressed protein in the tissue will be compensating for 
degraded 7ND. Possible therapeutic effects obtained via administration of 7ND protein 
remain to be elucidated. 
 
7ND is a well characterized inhibitor of the CCL2/CCR2 axis in human in vitro 
models, such as inhibition of calcium release and cell migration induced by CCL2 in 
human monocytes (THP-1 cell line). Furthermore, 7ND was shown to bind to the 
human CCR2 receptor expressed on THP-1 and CCR2-transfected cell lines with high 
affinty [141]. However, the main hypothesis put forward was that 7ND attenuates the 
function of CCL2 by heterodimerization and thereby inhibits CCL2 from binding to the 
receptor [143].  
 
In contrast, 7ND is much less investigated in murine in vitro models and further 
analysis remain to clarify the mechanisms of the therapeutic effects in vivo (paper III). 
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4.4 CCL2/CCR2 in fibrosis 
 
CCL2/CCR2 mediated activation of human fibroblasts  
 
Various chemokines and their receptors have been associated with fibrosis and this is 
true also for CCL2 and its receptor. They have been reported to be involved in several 
fibrotic disorders such as systemic scleroderma (SSc) and idiopathic pulmonary fibrosis 
(IPF). SSc is a fibrotic disease of unknown aetiology affecting the skin and internal 
organs. Numerous groups have shown that increased levels of CCL2 are found in the 
skin of SSc patients. In early phases of the disease, the major source of CCL2 was 
reported to be infiltrating mononuclear cells. With progression activated fibroblasts 
become the major source of CCL2. In addition, increased levels of CCL2 have also 
been detected in the blood of SSc patients especially those in patients with pulmonary 
fibrosis [168]. 
 
One of the challenges in fibrosis research is the enormous complexity of the 
interactions and interplays between different cell types e.g. inflammatory leukocytes, 
various subtypes of fibroblasts and a large number of mediators such as 
cytokines/chemokines and their receptors. The CCL2/CCR2 axis is one component that 
may have implications in the initiation and the progress of fibrosis. One hypothesis is 
that CCL2 plays an important role as a chemoattractant of inflammatory cells in fibrotic 
tissue. Local expression of CCL2 in the skin of SSc patients may induce migration of 
inflammatory cells into the skin, mainly T-cells and macrophages, which in turn secrete 
profibrotic mediators leading to activation of resident fibroblasts and accumulation of 
extracellular matrix proteins and fibrosis. This is shown in vitro with fibroblasts 
explanted from SSc patients promoting recruitment of mononuclear leukocytes by 
release of CCL2. Migration was inhibited by CCL2 blocking antibodies showing that 
CCL2 was the major chemoattractant [168, 169]. 
 
CCL2 may also be a mediator of other cellular events involved in fibrosis, a hypothesis 
that has been intensively investigated, but still there are several questions that remain to 
be answered. Much of the research has focused on the role of CCL2 in fibroblast 
activation, the precise fibroblast subtype involved, and whether CCL2 mediates its 
effects via CCR2 or via not yet identified receptors. CCR2 is not found in all fibroblasts 
but has been detected in certain fibroblast subtypes. Fibrocytes, fibroblasts precursors, 
isolated from human and murine peripheral blood were shown to express leukocyte as 
well as mesenchymal markers on their surface and in addition, they expressed the 
CCR2 receptor [160]. CCL2 stimulation of human fibrocytes was found to increase 
fibrocyte proliferation as well as differentiation into fibroblast phenotype that may 
implicate their role in fibrotic disease. 
 
Moreover, it has been shown that it is possible to isolate CCR2 positive fibroblast 
precursor cells (pericytes), explanted from skin tissue biopsies of early stage dcSSc 
(diffuse cutaneous systemic scleroderma) patients. In contrast, no CCR2 positive 
pericytes were isolated from late stage dcSSc or limited forms of SSc. CCR2 
expressing fibroblasts were reported to over-express α-SMA and were able to 
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differentiate to myofibroblasts, but with differentiation they seemed to lose expression 
of CCR2. By specific inhibition of CCL2 or CCR2 using an anti CCL2 antibody or a 
receptor antagonist respectively, the base level of α-SMA was attenuated, suggesting 
an autocrine activation of the fibroblast via CCL2/CCR2 [170]. 
 
In contrast, from another study it was reported that dermal fibroblasts isolated from SSc 
patients were not activated by CCL2, no collagen I production was upregulated in 
fibroblasts from either healthy individuals or patients with SSc [169]. An interesting 
model to explain the role of CCL2 in fibrosis was proposed by the authors; increased 
levels of PDGF and IL-1β in fibrotic tissue induce an over-expression of CCL2 in 
dermal fibroblasts that in turn induces a Th2 differentiation of infiltrating Th0 cells. 
Th2 cells release large amounts of IL-4 that stimulates synthesis of collagen in 
fibroblasts [171].  
 
As mentioned, CCL2/CCR2 has also been reported to have implications in fibrotic lung 
disease such as IPF and usual interstitial pneumonia (UIP). Fibroblasts explanted from 
biopsies of fibrotic and nonfibrotic patients were studied and it was shown that 
fibroblasts explanted from IPF/UIP patients exhibited upregulated levels of several 
fibrotic markers compared with those from nonfibrotic lung tissue. Moreover, fibrotic 
fibroblasts were hyperresponsive to stimulation with profibrotic mediators such as 
TGFβ and IL-13 but also CCL2, upregulating fibrotic markers multiple folds. In 
contrast, fibroblasts from non fibrotic patients were more or less unresponsive to these 
stimulus [172]. TGFβ1R, TGFβ2R, IL-13αR1 and IL-13αR2 were all upregulated in 
UIP/IPF fibroblasts which may explain the increased responsiveness of IL-13 and 
TGFβ. Interestingly no CCR2 transcript was found in any of the fibroblast cell lines but 
receptor protein was detected using immunohistochemical staining. Neutralization of 
CCL2 in unstimulated fibrotic fibroblasts had no effect on expression levels of fibrotic 
markers, however, CCL2 neutralization led to a moderate downregulation of TGFβ 
induced α-SMA and TGFβ1 gene expression indicating an interplay between TGFβ 
and CCL2. Whether this downregulation is mediated via CCR2 or via another 
mechanism was not shown.  
 
CCL2/CCR2 in murine fibrotic in vivo models 
 
The role of CCL2/CCR2 in murine fibrosis has also been studied in CCR2-/- and CCL2/- 
knockout mice. Pulmonary fibrosis is simulated in mice with intratracheal 
administration of FITC isomer I or bleomycin resulting in acute lung inflammation and 
extracellular matrix deposition [173, 174]. CCR2-/- knockout and wild-type animals 
were induced with bleomycin or FITC by intratracheal administration and it was shown 
that the knockouts were protected from lung fibrosis, exhibiting a significantly lower 
degree of inflammatory exudates and collagen in lung tissue. The protection from 
fibrosis was not primarily mediated by reduction of recruitment of inflammatory cells 
but rather by adjusting the balance of expression of cytokines such as TNFα [175]. In 
addition, fibroblast populations isolated from lung tissue of FITC-induced CCR2-/- and 
wild-type mice have been studied [175, 176]. A higher level of fibrocytes in wild-type 
mice was identified, indicating that CCR2 may be responsible for the recruitment of 
fibrocytes to FITC-induced lung tissue. 
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The CCL2-/-knockout mouse was compared with the wild-type mouse in a skin fibrosis 
model. Mice were subcutaneously injected with bleomycin into the dorsal skin daily for 
four weeks. The CCL2-/- knockout was also in this case shown to be protected from 
fibrosis compared with the wild-type. While the wild-type developed an accumulation 
of collagen in the dermis and replacement of fat with connective tissue, the knockout 
exhibited less fibrotic tissue and preserved partially the subcutaneous fat. In this study it 
was also found that the CCL2-/- mouse exhibited a lower degree of infiltration of 
inflammatory cells such as neutrophils and monocytes into the inflamed tissue. 
Increased levels of CCL2 and TGFβ explain the increased recruitment of monocytes, 
activation of macrophages and differentiation of fibroblasts to myofibroblasts in wild-
type mice. The authors also observed a shift in the balance between expression of 
MMPs and their inhibitors (TIMPs). As this balance is crucial for the turnover of the 
extracellular matrix, the shift in the balance observed in the CCL2-/- mouse might (at 
least partly) explain the protection against fibrosis [177].  
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5 AIM OF THESIS 
 
The aim of the studies was to identify and characterize modulators of two 
chemoattractant receptors, FPR2 and CCR2 in order to investigate them as potential 
drug targets.  
 
Paper I 
 
The FPR2 receptor was previously described to mediate unique anti-inflammatory and 
proresolution properties through activation by receptor agonists of different chemical 
structures such as LXA4, annexin A1 and small molecules. The main goal of the study 
was to identify FPR2 agonists with lipoxin-like anti-inflammatory and proresolution 
properties. Another goal was to characterize selected hits in terms of selectivity and  
receptor hierarchy (FPR2 versus FPR1).  
 
Paper II 
 
The aim of this study was to screen for FPR2 antagonists and investigate if selected 
hits could be attributed to anti-inflammatory properties. 
Another goal was to characterize the inhibitors in terms of anti-inflammatory properties 
and selectivity (FPR1 versus FPR2).  
 
Paper III 
 
The truncated form of CCL2 (1,9-76), also named 7ND, was described as an antagonist 
of human CCR2 in in vitro models. 7ND, administered by gene transfection was 
described to exhibit therapeutic effects in numerous in vivo models such as bleomycin-
induced fibrosis. However, the mechanism of 7ND´s therapeutic effects in vivo has not 
been characterized and the interaction between 7ND and the murine CCR2 has not 
been described. One goal was to investigate if 7ND also inhibits the murine CCR2 
receptor and the mechanism of such inhibition. 
Another goal was to investigate if 7ND mediates antifibrotic effects directly on 
fibroblasts isolated from bleomycin-induced mice. 
 
Paper IV 
   
CCL2 has in several studies been described as a profibrotic mediator. It has been shown 
to upregulate synthesis of ECM proteins in fibroblasts, explanted from tissues of 
patients with fibroproliferative diseases. The aim of this investigation was to find out 
how CCL2 activates human fibroblasts of different origins in terms of fibrotic markers. 
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6 RESULTS AND DISCUSSION 
 
6.1 Identification and characterization of FPR agonists-
paper I 
 
Screening for FPR2 agonists 
 
The goal of the present investigation was to develop selective FPR2 agonists with 
lipoxin-like, anti-inflammatory and proresolution properties. As the potential ligands of 
FPR2 may be small molecules, eicosanoid lipids as well as peptides, different 
approaches are possible to apply in order to address this receptor. The selected strategy 
was to screen for FPR2 small molecule agonists that replicate the proresolution/anti-
inflammatory properties reported for LXA4.  The decision was primarily based on the 
high probability of success finding small molecule modulators to a GPCR Family A 
receptor and the extensive prior experience from our lab in working with this target 
family.  Other considerations were the potential of the new agent to be orally available 
in addition to the relatively beneficial future production costs.  
In this section preliminary and published data are discussed. 
 
A small molecule library of 50 000 compounds were screened for FPR2 selective 
agonists. FPR2 transfected CHO cells (Chinese hamster ovary cells) were stimulated 
with each compound at a single concentration and the elicited intracellular calcium 
release was measured in FLIPR. 500 compounds, confirmed as agonist hits were 
counter screened in the parental cell line to exclude hits with non-specific receptor 
activity. 
 
The five most potent receptor specific screen hits (compounds 5, 6, 8, 9 and 10), 
together with another five previously described FPR2 agonists, (compounds 1, 2, 3, 4 
and 7) representing different chemical scaffolds, were selected for further analysis. 
ATL (aspirin-triggered lipoxin) and WKYMVm were included as reference 
compounds, representing differential signaling by the FPR2 receptor [97]. 
Structures of the compounds are described in paper I. Compound 1, 2 (enantiomers of 
Acadia C7) and 7, identified by screening small molecule libraries for FPR2 specific 
receptor activation in FPR2-transfected NIH3T3 cells, have been shown to dose 
dependently prevent hyperalgesia induced by carrageenan in a rat model (reference 
see paper I). Compound 3, a substituted quinazinolione (QuinC1), a FPR2 specific 
agonist has been described to be chemotactic and induce degranulation in neutrophils, 
but unable to stimulate superoxide production [134, 178]. A pyrazolone, compound 4, 
was identified by screening a small compound library for calcium release elicited by 
compound stimulated FPR2 and Gα15 co-transfected CHO cells. Compound 4 was 
reported to act anti-inflammatory; inhibiting fMLF and IL-8 induced cell migration in 
neutrophils. In addition, compound 4, named compound 43 in the reference, was also 
shown to be active in vivo and showed a dose dependent inhibition of ear swelling in 
mice following oral administration [133].   
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All twelve compounds were analyzed for dose dependent calcium release in 
FPR2/Gα16 transfected cells and EC50 values were determined. All compounds, 
except ATL were shown to induce calcium release in a dose dependent manner (Table 
3) with EC50 values spanning from 6 nM to 230 nM. This interesting result of ATL 
was not that surprising; another group had previously made similar findings, that ATL 
is a very low affinity inducer of calcium release in FPR2-transfected cells [179].  
Next step was to analyze receptor selectivity, FPR2 versus FPR1. It was determined for 
compound 1-10 in a calcium release assay in FPR1/Gα16  transfected cells. All 
compounds, except compound 9 induced calcium release with EC50 values from 9 nM 
to 9 µM The three most potent FPR2 agonists, compounds 4, 5 and 10 displayed 
different profiles, 4 and 5 were shown to be equipotent agonists of FPR1 and FPR2 
while compound 10 was selective for FPR2 (Table 3).  
   
Compound  FPR2 Calcium  FPR1 Calcium*  
No EC50 (M) EC50 (M) 
1 3,4E-08 6,4E-06 
2 3,2E-08 5,4E-06 
3 3,9E-08 8,9E-06 
4 4,2E-09 9,1E-09 
5 6,0E-09 2,1E-08 
6 3,9E-08 1,9E-07 
7 4,5E-08 9,3E-06 
8 1,0E-07 2,9E-06 
9 2,3E-07 no response 
10 6,0E-09 6,8E-06 
ATL (Lipoxin) > 5E-06* not analyzed 
WKYMVm 1,5E-09* not analyzed  
 
Table 3. Compounds 1-10 induce intracellular calcium release in FPR2 and FPR1 transfected CHO cells. 
CHO-K1 cells stably expressing the human FPR1 or FPR2 together with Gα16 were loaded with 3.6 µM 
Fluo4 AM (Molecular Probes, Eugene, OR), including 2,5 mM probenecid (SIGMA) for 60 min, at 37 C. 
In FLIPR 2 (Molecular Devices) cells were stimulated with compounds in a dose dependent manner from 
20 µM to 3.4 pikomolar in 11 step and changes of cytosolic calcium were measured.  
ATL (Calbiochem) (stock 709 µM in ETOH) was diluted in HBSS in 11 steps and cells were stimulated 
with ATL from 5 µM to 0.85 pM final concentrations. WKYMVm (Tocris) was diluted in HBSS and 
cells were stimulated with 100 nM to 1.7 pM final concentration. n=3, * Preliminary data 
 
Analysis of pro- or anti-inflammatory properties 
 
Next step was to analyze the agonists with respect to pro and anti-inflammatory 
properties. SAA, a proinflammatory mediator described as a FPR2 agonist was reported 
to induce IL-8 secretion in primary neutrophils, and stable lipoxin analogues were 
shown inhibit this response [92, 93]. Thus, compound-stimulated IL-8 release was 
considered to be an appropriate method to use for evaluation of our hits.  
Compound 4-10, ATL and WKYMVm were analyzed for secretion of IL-8 in primary 
neutrophils. Compounds 4-7, 10 and WKYMVm were all shown to significantly induce 
IL-8 secretion (Figure 7 A). Accordingly, the most potent inducers of calcium release 
in FPR2 transfected cells, compounds 4, 5, 10 and WKYMVm were also the most 
potent inducers of IL-8 secretion. As expected, ATL at1 µM did not induce IL-8 
secretion (Figure 7B) [97]. 
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Figure 7. Preliminary data. Compounds 4-7 and 10 induce Il-8 secretion in primary neutrophils (A). ATL 
at 1 µM did not induce IL-8 secretion compared to control (B). 
Neutrophil granulocytes, prepared from buffy coat and isolated in a Ficoll-Paque gradient, were provided 
from 3H Biomedical (Uppsala, Sweden). Neutrophils were diluted to 5 x 106 cells/ml in assay buffer, 
1xHBSS (GIBCO, 14180046) including HEPES (GIBCO, 15630049), and plated at a cell concentration 
of 400 000 cells/well in 96 well plates (Costar, 3599). Compounds dissolved in DMSO at a concentration 
of 10 mM were diluted in assay buffer to 200 µM and further stepwise to 2.56 nM. ATL (Calbiochem) 
(stock 709 µM in ETOH) was diluted in HBSS  to 1 µM. Cells were stimulated with compounds at final 
concentrations from 20 µM to 0.256 nM and ATL at 1 µM  for 4 hours. ETOH ctrl was 0.14 % ETOH in 
HBSS.  DMSO blank was 0.2 % DMSO. After stimulation cells were centrifuged at 250 g for 5 minutes 
and IL-8 concentration in the supernatant was determined using a ready-to-use HTRF kit (CisBio, 
62IL8PEB). The FRET read-out, proportional to the IL-8 concentration, was measured in an EnVision 
2102 multilabel reader (Perkin Elmer). IL-8 concentration was plotted as a function of compound 
concentration. Values are the mean+ SEM.*,P<0.05,**,P<0.01,***,P<0.001. 
 
 
To further confirm the proinflammatory character of the compounds, they were 
analyzed for induction of NADPH oxidase activity (paper I). Isolated human 
neutrophils were stimulated with compound (1-10) and secretion of superoxide anions 
was measured using a previously described method (isoluminol-enhanced 
chemiluminescence) [180]. fMLF, the reference compound of this study, together with  
compounds 1-10, were all shown to induce NADPH-oxidase activity in primary 
neutrophils. The same correlation that was observed between calcium release in FPR2 
transfected cells and IL-8 release in neutrophils, was observed in the NADPH oxidase 
analysis. Compounds 8 and 9 induced a respiratory burst only in TNFα-primed cells 
and at concentrations higher that 1 µM, whereas the compounds 1, 2, 3, 6 and 7 
triggered also resting cells to produce superoxide anions (data not shown). The three 
most potent compounds 4, 5 and 10 induced a robust NADPH oxidase response in 
resting cells (Figure 8). ATL was not included in this study since it had previously 
been reported to not induce ROS secretion in human neutrophils [97, 181]. 
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Figure 8. Activation of NADPH oxidase in neutrophils. Cells were preincubated for 5 minutes at 370 C 
and then challenged with 1 µM of compound 4, 5 and 10 or 100 nM fMLF. 
 
Furthermore, compounds 4, 5 and 10 were analyzed for two other proinflammatory 
events in neutrophils, mobilization of surface CR3 and induction of cell migration in 
the same cells. Accordingly, compound 5 was the most potent inducer of chemotaxis 
while compound 4 was the most potent inducer of CR3 mobilization. 
 
Taken together, our results demonstrated that compounds 4-7 and 10 were all able to 
induce proinflammatory actions in primary neutrophils. In addition, there was a 
correlation between the potency of the compounds in the calcium release assay in FPR2 
transfected cells and their ability to induce proinflammatory events in neutrohils. To 
our surprise, compound 4, described as an anti-inflammatory compound in both in vitro 
and in vivo models, demonstrated another profile in our hands. Compound 4 was, in 
contrast to described data [133], an equipotent inducer of calcium release in  FPR2 and 
FPR1 transfected cell lines and in addition, able to induce proinflammatory activities in 
neutrophils.  
Based on these findings, the goal of the project was changed. The new goal was to 
further characterize compounds  4, 5 and 10 in order to understand via which receptor, 
FPR1 or FPR2, that these compounds mediate their effects in neutrophils. 
 
Receptor selectivity-FPR1 versus FPR2 
 
Receptor selectivity in neutrophils was determined by measurements of compound- 
induced NADPH oxidase activity in presence of receptor specific 
inhibitors/antagonists, PBP10 and WRWWWW (FPR2) and cyclosporine H (FPR1) 
(described in 3.4). Data showed that NADPH oxidase activity induced by compounds 
4, 5 and 10 was completely blocked by cyclosporine H demonstrating that all 
compounds were activating FPR1. This is in line with calcium release data in 
transfected cell lines except for compound 10. Furthermore, the FPR2 specific inhibitor 
WRWWWW was shown to be a partial inhibitor of compound induced responses, but 
surprisingly, PBP10 did not block the responses at all. These data led to further 
investigations. 
 
free supernatant (with 10 mM from the beginning), compared to
the corresponding control pre-incubated without any cells. The
activities induced by the three compounds were, however,
basically unchanged after interaction with the neutrophils
(Fig. 3; Table 1) whereas the triggering effect of fMLF in a
comparable systemwas reduced bymore than 75% and a complete
inactivation of WKYMVM (Fig. 3D; Table 1) was obtained.
We know from earlier studies that the inactivation is dependent
on the granule enzyme MPO [14], but no MPO secretion was
induced by any of the compounds used (data not shown),
suggesting that the basal level MPO is sufficient. Moreover, the
neutrophil activity induced by a cell free supernatant, originating
from a mixture of cells, WKYMVM (an FPR2 agonist) and
compound 5 (primarily an FPR1 agonist; see below) was totally
inhibited by cyclosporine H (an FPR1 antagonist), showing that
when one sensitive and one stable agonist are added to the cells
simultaneously, only one of them ‘‘survives’’.
[(Fig._2)TD$FIG]
Fig. 2. Activation of the neutrophil NADPH-oxidase by the compounds 4, 5, and 10.
Neutrophils were pre-incubated at 37 8C for 5 min and then challenged with the
ago ists (1mM final concentratio ). The extrace lular release of su eroxide anion
was monitored. The time point for addition of the agonist is indicated by an arrow
and the amount of superoxide is expressed in arbitrary units. For comparison the
response induced by the prototype agonist fMLF (10!7 M final concentration) is
shown in the inset. Abscissa; time of study (min); ordinate; superoxide production
given as light emission and expressed in cpmx10!6.
Table 1
Neutrophil-mediated inactivation of fMLF, WKYMVM, compound 4, compound 5
and compound 13. The agonists were added to neutrophils, and after an incubation
period of 10min, the cells were removed by centrifugation and the agonists
remaining in the supernatants were used to trigger a new/fresh sample of cells to
generate ROS and the activities were compared to a control sample of the respective
compound. The ratios were calculated (using the peak values of the response)
between samples incubated with cells and the controls, and a value of 1 is expected
for compounds that are resistant to inactivation whereas those that are fully
inactivated will have a ratio value close to 0.
Agonist incubated with neutrophils Ratio (mean" SD, n)
The FPR1 agonist fMLF (10!6) 0.19"0.25, n =8
The FRP2 agonist WKYMVM (10!6M) 0.07" 0.02, n =4
Compound 4 (10!5M) 1.01"0.10, n =4
Compound 5 (10!5M) 1.02"0.09, n =4
Compound 13 (10!5) 0.76"0.09, n =4
[(Fig._3)TD$FIG]
Fig. 3. Compound 4, 5 and 10 are not inactivated by the neutrophils. Neutrophils (107/ml) were incubated at 37 8C for 10 min with compound 4, 5 or 10 (10 mM final
concentration; A–C) or WKYMVM (1mM final concentration; D). The cells were then removed by centrifugation and the supernatants were used to trigger freshly prepared
cell samples. The cell-free supernatant containing compound 4, 5 or 10 induced a respiratory burst (broken line in the upper panel) comparable to the control sample (solid
line), whereas no activity was induced by the cell-free supernatant containing WKYMVM from the beginning (broken line in the lower panel). The time point for addition of
the supernatant or control agonist is indicated by arrows and the amount of superoxide is expressed in arbitrary units. Abscissa; time of study (min); ordinate; superoxide
production given as light emission and expressed in cpmx10!6.
H. Forsman et al. / Biochemical Pharmacology 81 (2011) 402–411406
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To elucidate the preferred receptor of compounds 4, 5 and 10 in primary neutrophils, 
homologue desensitization studies were performed (paper I). Neutrophils were first 
challenged with fMLF followed by stimulation with compounds and measurement of 
NADPH oxidase activity. For all three compounds the responses were completely 
desensitized. When fMLF and the compounds were added in reverse order the 
responses were still completely abolished. These data demonstrate that compounds 4, 
5, and 10 were all activating FPR1 at this concentration. When neutrophils were 
stimulated with WKYMVM followed by compound stimulation, the responses were 
completely abolished. In contrast, when WKYMVM and compounds were added in 
reverse order, the responses were partially inhibited. These results indicate that 
compounds 4, 5 and 10 activate both FPR1 and FPR2 but may have a preference for 
FPR1.  
 
Taken together, this study showed that compounds 4 and 5 were high potent agonists of 
FPR1 as well as FPR2 in a calcium release assay in transfected cell lines. In contrast, 
compound 10 demonstrated a much higher affinity to FPR2 than FPR1 in transfected 
cells. However, in primary neutrophils where both receptors were present, the receptor 
preference was slightly different. Use of receptor specific antagonists and 
desensitization studies indicate that all three compounds activate both receptors for 
induction of NADPH oxidase activity, but may use FPR1 as the preferred one. 
 
6.2 Identification and characterization of selective FPR 
inhibitors - paper II 
 
Screening for FPR2 antagonists 
 
The first goal of this study was to evaluate if screening a small molecule library for 
FPR2 antagonists would be a feasible approach for identification of new anti-
inflammatory compounds. A successful example is the small molecule FPR2 
antagonist that was recently described to exhibit anti-inflammatory effects in vivo 
[134, 182]. That data, together with the outcome of the FPR2 agonist screen supported 
this approach, screening a small molecule library (20 000 compounds) for FPR2 
antagonists. The second goal was to characterize screen hits in order to elucidate 
receptor selectivity in neutrophils. 
 
FPR2/Gα16  transfected CHO cells were stimulated with a small molecule library 
and challenged with 2 nM WKYMVm followed by measuring the calcium release in 
FLIPR (method described in paper I). Few screen hits were identified. However, two 
structurally related compounds (salicyl-anilides), BVT015825 and BVT174332, shown 
to inhibit WKYMVm-induced calcium release in a dose- dependent manner, were 
selected (data not shown).  
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Analysis for anti-inflammatory properties 
 
Selected hits were further analyzed for anti-inflammatory properties. BVT015825 and 
BVT174332 were analyzed for inhibition of LPS-stimulated and WKYMVm 
stimulated IL-8 secretion in neutrophils. BVT015825 and BVT174332 were shown to 
inhibit WKYMVm -stimulated as well as LPS-stimulated IL-8 secretion in human 
neutrophils. Interestingly, in opposite to what had been described previously, ATL did 
not exhibit any inhibitory effects on LPS-stimulated IL-8 secretion (preliminary data, 
figure 9) [183].  
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Figure 9. Preliminary data. Compounds selected from a small library screen, BVT174332, BVT015825 
together with ATL were evaluated for inhibition of LPS (A, C and E) and WKYMVm (B, D )-stimulated 
IL-8 secretion. Preparations of neutrophils as well as measurement of IL-8 were performed according to 
the method described in Figure 7. Cells were stimulated at final concentrations from 20 µM to 0.256 nM 
for 15 minutes with compounds prior to stimulation with 1 µg/ml of LPS (Sigma, L4516) or 1 µM of 
WKYMVm (Innovagen, SP-WPEP-1) or controls for another 4 hours. IL-8 concentration was plotted as 
a function of compound concentration (n=2). 
 
Receptor selectivity-FPR1 versus FPR2 
 
To further explore the structure activity relationship and hopefully be able to identify 
new selective inhibitors, a set of 44 structurally similar compounds to BVT174332 and 
BVT015825 was selected. These compounds were analyzed for inhibition of NADPH 
oxidase activity in primary neutrophils, in presence of fMLF or WKYMVM in order to 
determine potency as well as receptor selectivity (FPR2 versus FPR1) (paper II). One 
of these, BVT173187, was shown to be the most selective compound. It was selective 
for FPR1 signaling, inhibiting fMLF stimulated release of reactive oxygen species with 
an IC50 of 0.1 µM. When BVT173187 was compared with cyclosporine H it was 
shown that the IC50 values of the two compounds were the same. Selectivity was 
determined at 1 µM of BVT173187 in presence of either 100 nM of fMLF or 100 nM 
of WKYMVM. Inhibition induced was defined as the ratio of the peak values of the 
agonist responses in presence or absence of antagonist according to a recently described 
tool for analysis of receptor specific events [184].  
The ratio fMLF/fMLF+BVT173187 was 20,7 while the ratio for 
WKYMVM/WKYMVM+BVT173187 was 1,3, suggesting a strong preference for 
inhibition of FPR1 signaling (Figure 11). However, BVT173187 was also inhibiting 
NADPH oxidase triggered by C5a and IL-8 indicating that it was acting also via the 
CXCR1/ CXCR2 and C5a receptors. BVT015825 did not inhibit superoxide release 
induced by fMLF or WKYMVM. BVT174332 was a partial inhibitor of superoxide 
release induced by fMLF (Table 4). 
 
Taken together, the structurally related compounds BVT174332, BVT015825 and 
BVT173187, all inhibited proinflammatory actions in neutrophils. Interestingly, they 
are structurally related to IMD0354 (Figure 10) a salicyl-anilide that was described as a 
cell permeable IKKβ (inhibitor of nuclear factor-κB kinase subunit) inhibitor and has 
demonstrated anti-allergic and anti-inflammatory effects in a mouse model of allergic 
inflammation [185]. This indicates that also BVT173187, BVT174332 and 
BVT015825 may be taken up by the cell acting downstream the receptors. Thus, it 
remains to determine in further studies the exact mechanisms of action of these 
compounds. 
 
 
 
Figure 10.  Salicyl-anilides exhibit anti-inflammatory actions in vivo (IMD0354) and in vitro 
(BVT015825, BVT174332 and BVT173187).  
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Figure 11. FPR1 is the preferred receptor over FPR2. Neutrophils were incubated in presence or absence 
of 1 µM BVT173187 and challenged with 100 nM fMLF or 100 nM WKYMVM and the production of 
superoxide anion was monitored. n=4 
 
 
                                                                        Ratio 
BVT174332 
fMLF/WKYMVM  1.1 
fMLF/fMLF+BVT174332  2.7 
WKYMVM/WKYMVM+ BVT174332 0.9 
 
BVT173187 
fMLF/WKYMVM  1.2 
fMLF/fMLF+BVT173187  20.7 
WKYMVM/WKYMVM+ BVT173187 1.3 
 
BVT015825      
fMLF/WKYMVM  0.9 
fMLF/fMLF+BVT015825  1.2 
WKYMVM/WKYMVM+ BVT015825 0.7 
 
Table 4. BVT174332 and BVT173187 were shown to inhibit fMLF-stimulated superoxide in neutrophils. 
Inhibition and selectivity was determined for BVT0158251, BVT17433 and BVT173187 in presence of 
either fMLF or WKYMVM. Inhibition induced was defined as the ratio of the peak values of the agonist 
responses in presence or absence of antagonist according to a recently described tool for analysis of 
receptor specific events [184].  
 
   
 
 
 
 
 
 
The shift in the ratio was, thus due to a selective effect on the
fMLF-induced response and the IC50 value was determined to
around 0.1 mM. A working solution of 0.3 mM was chosen for the
basic characterization of the inhibitory compound, and with this
concentration the fMLF-induced NADPH-oxidase activity (mediat-
ed through FPR1) was routinely inhibited by around 90%, whereas
there was no effect on the WKYMVM induced response (mediated
through FPR2).
The inhibitory activity of 44 analogues to BVT173187 was
investigated using one single concentration (0.3 mM; Supplemen-
tary Fig. 2).
3.2. FPR1 is the preferred over FPR2 but the IL-8 and C5a receptors are
also affected by BVT173187
Neutrophils express in addition to FPR1 and FPR2 a number of
other GPCR/chemotactic receptors. In order to determine if the
activity mediated by other receptors was affected by BVT173187,
we used IL-8 and C5a, two well known receptor specific agonists
binding to CXCR and C5aR, respectively. The triggering through
CXCR (the IL-8 receptor), showed reduced oxidase activity in the
presence of BVT173187 (Fig. 3A and C) and this was true also for
the response triggered through the C5aR (Fig. 3B and D). The IC50
value for the IL-8 induced response was >1 mM and for the C5a
induced response around 0.5 mM.
3.3. The FPR1 inhibitor BVT173187 affects mobilization of
complem nt receptor 3 (CR3)
Neutrophil activation by chemoattractants is associated with
an induction of granule secretion, and such a process leads to a
mobilization of new receptors to the cell surface. To characterize
BVT173187 with respect to its ability to inhibit granule mobiliza-
tion, we examined the effect of surface exposure of CR3, a marker
protein localized in easily mobilized granules in neutrophils (i.e.
secretory vesicles, gelatinase granules, and to some extent specific
granules), upon stimulation with fMLF and WKYMVM, FPR1 and
FPR2 specific agonists, respectively. These receptor agonists induce
an increase in CR3 exposure (Fig. 4A), and BVT173187 inhibited to
a large extent this increase when induced by fMLF but was without
effect of the WKYMVM induced CR3 exposure (Fig. 4B).
3.4. Comparison between the inhibitory effects of cyclosporine H and
BVT173187
The cyclic undecapeptide, cyclosporine H, is a potent FPR1
selective receptor antagonist [17]. Accordingly, this antagonist
inhibits fMLF-induced superoxide anion secretion in human
neutrophils (see Fig. 1). Our results as well as those of others
[13,26,27] show that cyclosporine H is a more potent FPR1
selective antagonist than other earlier described antagonists such
as the peptides BocPLPLP and BocMLF. We have now compared the
inhibitory effect of BVT173187 with that of cyclosporine H. The
IC50 values for the two inhibitors were the same (Fig. 5), and the
new inhibitor is, thus, a just as potent FPR1 inhibitor as
cyclosporine H. We have earlier shown that cyclosporine H is
without effect on FPR2 induced neutrophil activity in concentra-
tions up to 1 mM [13], and this was true also for BVT173187 (Fig. 5).
To determine the effect of BVT173187 on peptide binding, a FITC-
conjugated formylated peptide (FITC-fNLPNTL; 10!9 M final con-
centration) was added and the amount of bound probe (mean
fluorescence intensity; MFI) was determined by flow cytometry. The
binding was specific, illustrated by the fact that an excess of non-
labeled fMLF (0.1 mM final concentration) but not of WKYMVM
reduced the binding of FITC-fNLPNTL (data not shown). The presence
of BVT173187 (from 0.3 mM up to 1 mM final concentration) during
Fig. 2. Structure (A) and function (B) of the new inhibitor 3,5-dichloro-N-(2-chloro-
5-methyl-phenyl)-2-hydroxy-benzamide (BVT173187). (A) Chemical structure of
BVT173187 in which the orthophenol has been marked with a frame. (B) The figure
shows one representative experiment out of many. Neutrophils were pre-incubated
(37 8C for 5 min) in the presence or absence of BVT173187 (1 mM final
concentration). Neutrophils were challenged with the FPR1 specific agonist fMLF
(10!7 M) or the FPR2 specific agonist WKYMVM (10!7 M), and the production/
release of superoxide anion was monitored. The agonists were added at the start of
the measurement and the amounts of superoxide produced are given in arbitrary
units (relative light emission expressed in cpm " 10!6). The ratio values given
represent mean values calculated from four different experiments. (C) Chemical
structure of cyclosporine H.
H. C¸evik-Aras et al. / Biochemical Pharmacology 83 (2012) 1655–16621658
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6.3 7ND-a modulator of the human but not the murine 
CCR2-paper III 
 
7ND, CCL2 (1, 9-76) has been administered with gene transfection and shown to have 
therapeutic effects in several animal in vivo models related to fibrosis and inflammatory 
diseases [163-167]. Thus, development of a peptide ligand, based on 7ND was 
considered to be an attractive approach targeting the CCL2/CCR2 axis.  
The goal of this study was to characterize how 7ND interacts with CCL2 and CCR2 of 
murine origin.  
 
7ND has previously been shown to bind human CCR2 with high affinity and in 
addition, antagonize CCL2 stimulated chemotaxis and calcium release in human 
monocytes [141]. However, the mechanism with which 7ND inhibits CCL2 stimulated 
chemotaxis of human monocytes is not fully understood. One hypothesis is that 7ND 
attenuates the CCL2 mediated effects by heterodimerization with soluble CCL2 and 
thereby blocks the binding of CCL2 to the receptor. Formation of CCL2/7ND 
heterodimers was demonstrated by SDS-PAGE analysis of coprecipitated FLAG-
labeled 7ND and radiolabeled human CCL2 in presence of an anti-FLAG antibody. In 
line with this, additional data indicate that 7ND was able to inhibit CCL2 in solution, 
but not cross-linked CCL2, from inducing cell migration of the THP-1 cell line [65, 
140, 143].  
 
 
 
Figure 12. Inhibition of CCL2- induced cell migration by 7ND was determined using Transwell 96-
well microplates of 5 mm pore size. Human CCL2 (3 nM) (!EC70 challenge dose) or buffer was added 
to the lower chambers. 7ND at concentrations between 0.1 and 1000 nM or buffer, resuspended with 
THP-cells (106 cells/ml) were added to the upper chambers and allowed to migrate for 4 h in 
humidified atmosphere (5% CO2) at 37 8C. Relative fluorescence (RFU), as a measure of migrated 
cells, was plotted as a function of 7ND concentration (n = 3) (paper III) 
 
However when it comes to the mechanisms with which 7ND mediates it effects in 
described in vivo models, much less is investigated. Although it is generally assumed, 
there are no data showing that 7ND is acting by a mechanism involving CCL2/CCR2 
in these models. The hypothesis of 7ND forming heterodimers with murine CCL2 was 
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described but has not been verified [163]. Thus, it still remains to show if 7ND 
mediates its effects via inhibition of murine CCL2 stimulated effects in murine models. 
  
Firstly, we have confirmed that 7ND inhibits human CCL2 stimulated calcium release 
as well as cell migration of a human monocyte cell line, THP-1 (Figure 12) (paper III). 
Next step was to investigate if 7ND inhibits mCCL2-stimulated effects in cells 
expressing murine CCR2. As we were not able to identify a murine cell line with high 
enough levels of endogenously expressed CCR2, we used a mCCR2 transfected cell 
line for these studies (paper III). 7ND was at first evaluated in a functional assay; 
inhibition of mCCL2 stimulated calcium release. Surprisingly, it was shown that 7ND 
inhibits mCCL2 stimulated calcium release with very low affinity (data not shown).  
 
Next step was to investigate if 7ND binds to mCCR2. In a displacement assay using 
125I-JE it was confirmed that mCCL2 binds to mCCR2 with high affinity [145]. In 
contrast, 7ND was confirmed, in accordance with calcium release data, to be a very low 
affinity binder of murine CCR2 (Figure 13) (paper III). 
 
 
 
 
Figure 13. Displacement of 125I-JE binding to mouse CCR2. The three peptides mCCL2, hCCL2 and 
7ND displaced 125I-mCCL2 with pKi values of 9.33 ± 0.22 (0.46 nM, n=4), 7.22 (60 nM, n=1), and >6 
(>1 uM, n=4), respectively. 
 
As mentioned, the hypothesis put forward is that 7ND inhibits CCL2 mediated effects 
by heterodimerization of the two ligands [143]. If this hypothesis could be confirmed, it 
would explain how 7ND interacts with mCCR2, and clarify the mechanisms with 
which 7ND mediates its effects in in vivo models.  
In order to study the interaction between 7ND and mCCL2, mCCL2 was immobilized 
on a dextran-free chip and binding kinetics was studied by the surface plasmon 
resonance (SPR) technology [186]. Heterodimerization was analyzed over a wide 
range of concentrations of 7ND and showed that 7ND binds to murine CCL2. 
However, the interaction between the two ligands was weak; the dissociation constant 
of the 7ND/mCCL2 complex was determined to 670 nM (paper III). To be able to 
confirm these data and determine the stoichiometry, further experiments remain, such 
as studies of the CCL2/7ND complex in solution.  
 
Taken together, 7ND dimerizes with murine CCL2 with low affinity and moreover, it 
binds with low affinity to the murine CCR2. Accordingly, we found that 7ND inhibits 
CCL2 stimulated calcium release in mouse CCR2 transfected cell line with low affinity 
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as well. From these data we concluded that 7ND mediates its effect via CCR2 in mice 
with low affinity and that 7ND probably acts via an alternate pathway with high 
potency in described murine models.  
 
Based on these data it was concluded that 7ND might have another role than inhibition 
of CCR2 expressing leukocytes in vivo. Based on the fact that CCL2 may be involved 
in activation of fibroblasts in fibrotic tissue [170, 172] and that the effects of 7ND on 
isolated fibroblasts are not well described, the effects of 7ND on murine fibroblasts 
isolated from bleomycin-induced mice were evaluated. Fibroblasts were isolated from 
lung tissue of bleomycin-induced fibrotic mice [173] and stimulated with 
subnanomolar concentrations of 7ND. The concentration range of 7ND was based on 
the plasma concentrations measured in a bleomycin-induced mouse model that had 
been 7ND gene transfected [163]. Interestingly, it was found that 7ND significantly 
downregulated markers associated with activated fibroblasts such as α-SMA, collagen I 
(Figure 14), collagen III and fibronectin. No CCR2 mRNA was detected in isolated 
fibroblasts indicating that these effects were independent of the receptor ( paper III). 
 
 
 
A   B 
 
Figure 14. 7ND inhibits mRNA expression levels of fibrotic markers in murine lung fibroblasts in a 
concentration dependent manner. Levels of mRNA transcripts were detected by real-time PCR. (A) a-
smooth muscle actin (B) Collagen I. Representative data of 1 of 3 experiments are presented and 
values are the mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.005. 
 
6.4  CCL2 mediated downregulation of human fibroblasts - 
paper IV 
As mentioned, previously reported results indicate that CCL2 promotes activation of 
fibroblasts explanted from fibrotic tissue of skin as well as lungs, while fibroblasts 
originating from non fibrotic tissue seem to be unresponsive [170, 172]. However, 
several questions remain to be answered and further research is needed to understand 
the role of CCL2 in activation of fibroblasts. Divergent results [169] in these in vitro 
studies may be explained with differences in experimental set-up such as preparation of 
the isolated cell lines, which may result in outgrowth of different fibroblast subtypes. 
Moreover, cell cultures in low passages may still contain mononuclear cells that secrete 
profibrotic mediators, e.g. TGFß, that stimulate fibroblasts. 
 
Another key question is whether CCL2 activates fibroblasts via CCR2 or other 
pathways. CCR2 expression has been attributed to fibroblast precursor cells, fibrocytes 
and pericytes, and with increased cultivation passages in vitro, cells transform and 
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CCR2 expression may diminish [176]. Moreover, fibroblasts explanted from patients in 
different stages of the disease, e.g. SSc, could have different status, e.g. with respect to 
CCR2 expression, and respond differentially.  
 
To further broaden our understanding of the effects of CCL2 on the fibroblast 
phenotype in general, three established fibroblast cell lines were studied (paper IV). 
The human fetal lung fibroblast (HFL-1) cell line is a commercially available cell line 
used for studies of the role of CCL2 in fibrosis. HFL-1 was described to respond to 
CCL2 stimulation with IL-6 secretion and increased survival following staurosporine-
induced apoptosis. The hypothesis put forward was that CCL2 contributes to fibrosis by 
production of the prosurvival cytokine IL-6 and inhibiting apoptosis in fibroblasts 
[187]. Using the HFL-1 cell line some interesting findings were made. When they were 
stimulated with CCL2, correlating decreased levels of transcripts of fibrotic markers 
such as collagen I and α-SMA were observed (paper IV). This was unexpected and led 
us to explore another two fibroblast subtypes, primary preadipocytes and primary 
human pulmonary fibroblasts (HPF) isolated from non fibrotic patients. Stimulation of 
preadipocytes with CCL2 also resulted in decreased levels of collagen I and α-SMA 
(Figure 15). Interestingly, neither CCR2 transcript nor protein was detected in any of 
these three fibroblast cell lines, indicating that CCL2-mediated effects in HFL-1 and 
preadipocytes were independent of CCR2. Human pulmonary fibroblasts were 
unresponsive to CCL2 in regards to collagen expression in accordance with results 
reported by Murray et al [172]. These results confirmed that CCL2, at least in in vitro 
models, activates fibroblasts differentially depending on origin and status of the cell. 
 
 
 
 
 
 
Figure 15. CCL2 inhibits mRNA expression levels of fibrotic markers in human fibroblasts in a 
concentration dependent manner. HPF, HFL-1 and preadipocytes were stimulated with human CCL2 
(1 and 60 nM). Levels of mRNA transcripts were detected by real-time PCR. A) α-smooth muscle 
actin, B) Collagen 1. 
Values are the mean+SEM.*,P<0.05,**,P<0.01,***,P<0.001. 
 
It is clear that CCL2 plays a role in the regulation of collagen turnover and ECM 
remodelling. Opposite to the described profibrotic effects in fibroblasts explanted from 
fibrotic patients, CCL2 has also been associated with downregulation of procollagen I 
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and TGFβ II receptor (TGFβRII) in skin fibroblasts. Ultraviolet light (UVB) exposure 
to skin fibroblasts induces upregulation of CCL2 and MMP1 transcripts and induces 
downregulation of mRNA expression of procollagen I and TGFβRII. MMP1 is 
responsible for degradation of procollagen I, and decreased levels of TGFβRII 
contribute to reduced TGFβ-stimulated expression of ECM [188]. In line with these 
results, Mithell et al presented data supporting the antifibrotic role of CCL2. CCR2-/- 
knockout mice demonstrated an attenuated resolution of CCL4-induced liver fibrosis 
compared to the wild-type mouse and these observations were shown to be caused by 
reduced levels of MMPs (MMP2 and MMP13) and persisting levels of TIMPs [189]. 
These studies support the conclusion that CCL2 is associated also with antifibrotic 
responses.  
 
The factors that regulate the way fibroblasts respond to proinflammatory (profibrotic) 
stimuli still remain to be explored. It was recently described that predipocytes and 
dermal fibroblasts, attributed to very similar fibroblast phenotypes, responded in an 
opposite manner to proinflammatory stimuli such as LPS and TNFα. While 
preadipocytes improve anti-inflammatory activities, dermal fibroblasts enhance 
inflammation [190].  
 
Taken together, these studies confirm that resident fibroblasts from non fibrotic 
individuals do not express CCR2. In addition, data confirm that primary resident lung 
fibroblasts from healthy individuals are unresponsive to CCL2. Interestingly, two other 
fibroblasts responded with downregulation of fibrotic markers. In order to better 
understand the consistency of these observations, essential follow-up experiments 
include extended time studies with an increased range of CCL2 concentration. To 
understand the relevance of these data it is valuable to analyze the underlying 
mechanisms and relate them to those of CCL2 mediated actions in a profibrotic 
context. Neutralization of CCL2 with a blocking antibody would further confirm if 
these effects are directly mediated by CCL2.  
 
6.5 Modulation of fibrotic markers in CCL2 and 7ND 
stimulated fibroblasts- paper III and IV 
 
As mentioned, CCL2 is described in several examples as a profibrotic factor acting via 
CCR2, that stimulates recruitment of inflammatory cells and precursors of fibroblasts 
into fibrotic tissue in human as well as murine models. 7ND was shown to be an 
antagonist of human CCR2 inhibiting calcium release and recruitment of inflammatory 
cells in vitro and in vivo. In contrast, 7ND exhibited low affinity to murine CCR2 but 
was still demonstrating inhibitory effects in murine fibroblasts, downregulating fibrotic 
markers. Interestingly, in accordance with 7ND, CCL2 stimulated similar effects in two 
human fibroblast cell lines of different origin, HFL-1 and preadipocytes. Accordingly, 
none of the fibroblasts, either of murine or human origin, were expressing the CCR2 
receptor (Figure 16). Apparently CCL2 and 7ND induce antifibrotic signaling in 
fibroblasts independently of CCR2 and thereby excluding uptake of CCL2 by non-
specific scavenger receptors. In order to identify the alternate pathways of CCL2 and 
7ND, further investigations are needed. Stimulation of fibroblasts in presence of 
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pertussis toxin would give some information whether another Gαi coupled chemokine 
receptor is involved or not. It has been shown previously that low concentrations of 
CCL2 induce cellular events in pancreatic beta cells as well as in vascular smooth 
muscle cells independently of CCR2 but via another pertussis toxin sensitive pathway 
[191, 192]. Panning of the chemokine receptor repertoire of the used fibroblasts would 
give us an idea about what other receptors that might come into play and from that 
information one may exclude one after the other. If this still does not give the answer, 
target fishing will be the next step [193]. 
 
 
 
Figure 16. CCL2 mediates infiltration of CCR2 positive fibroblast precursors to fibrotic tissue. Emerging 
evidences indicate that CCL2 also promotes profibrotic activation of subtypes of fibroblasts via CCR2. In 
addition, new observations indicate that CCL2 and its truncated analogue 7ND (1,9-76), promote 
antifibrotic activities in fibroblasts of two different origins, HFL-1 and preadipocytes independently of 
CCR2 (paper III and IV).  
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7 CONCLUDING REMARKS 
In present studies FPR2 and CCR2 have been investigated as potential targets in search 
of new anti-inflammatory and antifibrotic drugs. One goal was to identify anti-
inflammatory compounds by screening a small molecule library for FPR2 agonists. 
Promising reference compounds described as efficient anti-inflammatory agents in vitro 
and in vivo such as a pyrazolone, compound 4, was evaluated. In our hands the 
pyrazolone exhibited, in similarity with our selected most potent agonist hits, 
proinflammatory properties in several in vitro models. Moreover, the pyrazolone was 
also previously described to be relatively selective for FPR2 but we could show that it 
induced calcium release equally well in FPR1 as in FPR2 transfected cells. In addition, 
studies of receptor selectivity and hierarchy in primary neutrophils rather indicated a 
possible preference for the FPR1 receptor. These conflicting data brings insight into the 
fact that chemoattractants and their receptors may act differentially depending on what 
model is used. ATL described as a potent inhibitor of neutrophil activation in several in 
vitro models was, in our neutrophil model inactive. In line with this result, other 
conflicting data about the effects of LXA4 in neutrophils have recently been published 
[98]. 
 
FPR2 transfected cells were screened for receptor antagonists as well and a small group 
of structurally related compounds were identified that were shown to inhibit LPS-
stimulated IL-8 secretion in neutrophils. By using receptor specific tools, it was 
possible to show that one of them, BVT173187, demonstrated a clear preference for 
inhibition of FPR1 signaling, attenuating secretion of reactive oxygen as well as 
mobilization of CR3 in neutrophils. The complete mechanism of action of the 
compound though, remains to be determined. Future work will show if this compound, 
besides its therapeutic potential, could be a valuable tool in disclosing differences in 
signaling downstream the FPR1 and FPR2 receptors.  
 
CCL2 and its receptor CCR2 are major players for recruitment of monocytes to 
inflammatory sites. There are also emerging evidences for their involvement in 
development of fibrosis; CCL2/CCR2 axis is reported to promote fibrosis in several in 
vitro and in vivo models. Interestingly, observations have also been made that 
demonstrate antifibrotic actions by CCL2 in fibroblasts originating from non fibrotic 
patients. These effects were shown to be independent of CCR2. 
 
To address CCR2 in order to develop antifibrotic agents the selected approach was to 
evaluate the truncated form of CCL2 (1,9-76), 7ND that is described as a CCR2 
antagonist and has demonstrated efficacy in several in vivo models, e.g. bleomycin-
induced lung fibrosis. Surprisingly, it was found that 7ND is a very low affinity binder 
of the murine CCR2 homologue leading to the hypothesis that 7ND mediates its 
therapeutic effects in murine in vivo models independently of CCR2. From studies of 
7ND stimulated murine fibrotic lung fibroblasts, some interesting findings were made, 
that possibly can explain the pharmacological properties of 7ND in mice models. Our 
hypothesis is that 7ND acts as an inverse agonist that down-regulates the basal levels of 
  52 
α-SMA and extracellular matrix proteins, suggesting that 7ND may protect from 
development of fibrosis independently of CCR2. 
Notably, similar anti-fibrotic properties were observed for CCL2 on human CCR2 
negative fibroblasts. Although we are only at the beginning of understanding such a 
CCR2 independent pathway, a reasonable hypothesis could be that 7ND and CCL2 
share the same anti-fibrotic mechanism in this context, whereas CCL2 is a mediator of 
profibrotic responses via CCR2.  
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